Schwann Cell Bridges and Olfactory-Ensheathing Glia Grafts with Chondroitinase	11
Schwann Cell Bridges and Olfactory-Ensheathing Glia Grafts	11
Chondroitinase	75
Locomotor Recovery	99
Complete Transection	124
Damien D. Pearse3	255
,5 1University of Alberta	272
,5 1University	272
Alberta	290
Faculty	299
Rehabilitation Medicine	310
Edmonton	335
Canada T6G 2G4	345
2Brain Research Institute	361
University of Zurich	388
University	388
Zurich	402
Department of Biology	414
Department	414
Biology	428
Swiss Federal Institute	437
Technology , 8006 Zurich , Switzerland , and 3The Miami Project	464
Technology	464
8006 Zurich , Switzerland	476
3The Miami Project	506
Paralysis	533
4Departments of Cell Biology and Anatomy	544
4Departments	544
Cell Biology and Anatomy	560
5Neurological Surgery	589
University	612
Miami School	626
Medicine , Miami , Florida 33101	642
Numerous obstacles	674
successful regeneration of injured axons in the adult mammalian spinal cord	696
successful regeneration	696
injured axons in the adult mammalian spinal cord	723
injured axons	723
the adult mammalian spinal cord	740
a treatment strategy	793
axonal regeneration and significant functional recovery	823
axonal regeneration	823
significant functional recovery	847
spinal cord injury	885
these obstacles	920
The current study	937
multiple impediments	976
regeneration	1000
a combinatory strategy	1022
complete spinal cord transection in adult rats	1051
complete spinal cord transection	1051
adult rats	1087
reduce	1106
inhibitory cues	1113
the glial scar -LRB- chondroitinase ABC -RRB-	1132
the glial scar	1132
chondroitinase ABC	1148
a growth-supportive substrate	1184
axonal regeneration	1218
Schwann cells -LRB- SCs -RRB-	1239
Schwann cells	1239
SCs	1254
and	1261
regenerated axons	1279
the bridge to re-enter the spinal cord -LRB- olfactory ensheathing glia -RRB-	1305
the spinal cord -LRB- olfactory ensheathing glia -RRB-	1328
the spinal cord	1328
olfactory ensheathing glia	1345
The combination	1374
SC bridge , olfactory ensheathing glia , and chondroitinase ABC	1393
SC bridge	1393
olfactory ensheathing glia	1404
chondroitinase ABC	1436
significant benefit	1464
grafts only or the untreated group	1498
grafts only	1498
grafts	1498
the untreated group	1513
Significant improvements	1534
the Basso , Beattie , and Bresnahan score	1576
the Basso	1576
Beattie	1587
Bresnahan score	1600
forelimb/hindlimb coupling	1623
This recovery	1651
increased numbers of both myelinated axons in the SC bridge	1684
increased numbers	1684
both myelinated axons in the SC bridge	1705
both myelinated axons	1705
the SC bridge	1730
serotonergic fibers that grew through the bridge and into the caudal spinal cord	1748
serotonergic fibers	1748
the bridge	1786
the caudal spinal cord	1806
prominent descending tracts such as the corticospinal and reticulospinal tracts	1839
prominent descending tracts	1839
the corticospinal and reticulospinal tracts	1875
the bridge	1959
it	1971
other populations of regenerated fibers	1988
other populations	1988
regenerated fibers	2009
the driving force for the observed recovery	2033
the driving force	2033
the observed recovery	2055
there	2078
a significant correlation between numbers of myelinated fibers	2088
a significant correlation	2088
numbers of myelinated fibers	2122
numbers	2122
myelinated fibers	2133
the bridge	2154
coupling of forelimb and hindlimb as well as open-field locomotion	2178
coupling of forelimb and hindlimb	2178
coupling	2178
forelimb and hindlimb	2190
open-field locomotion	2223
Our study	2246
proven experimental treatments	2266
a well-established animal model	2309
needed direction	2357
the development of future combinatory treatment regimens	2378
the development	2378
future combinatory treatment regimens	2397
Introduction Spinal cord injury -LRB- SCI -RRB- in adult mammals	2438
Introduction Spinal cord injury	2438
Introduction	2438
Spinal cord injury	2451
SCI	2471
adult mammals	2479
complex pathophysiological processes	2503
extensive cell death , incomplete self-repair , and limited axonal regeneration	2557
extensive cell death	2557
incomplete self-repair	2579
limited axonal regeneration	2607
review	2640
Schwab and Bartholdi , 1996	2652
Schwab and Bartholdi	2652
1996	2674
These processes	2681
a combination of strategies	2710
a combination	2710
strategies	2727
ongoing tissue damage	2765
regrowth and reconnection of axons	2799
regrowth and reconnection	2799
axons	2828
Successful experimental interventions	2835
regeneration of axotomized axons	2889
regeneration	2889
axotomized axons	2905
the following	2937
blockade	2956
inhibitory cues	2968
the injury site	2991
the glial scar and myelin -LSB- e.g.	3017
the glial scar	3017
myelin	3036
chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	3050
chondroitin sulfate proteoglycans	3050
CSPGs	3085
NOGO , respectively -RSB-	3096
NOGO	3096
Fawcett and Asher	3117
1999	3136
Brosamle	3142
et al. , 2000	3151
et al.	3151
2000	3159
Merkler et al. , 2001	3165
Merkler	3165
et al. , 2001	3173
et al.	3173
2001	3181
Bradbury et al. , 2002	3187
Bradbury	3187
et al. , 2002	3196
et al.	3196
2002	3204
Li and Strittmatter , 2003	3210
Li and Strittmatter	3210
2003	3231
Silver and Miller	3237
Silver	3237
Miller	3248
2004	3256
supplementation	3267
growth-promoting cues	3286
neurotrophic factors	3316
Schnell	3338
et al. , 1994	3346
et al.	3346
1994	3354
Mocchetti and Wrathall , 1995	3360
Mocchetti and Wrathall	3360
1995	3384
Kobayashi et al. , 1997	3390
Kobayashi	3390
et al. , 1997	3400
et al.	3400
1997	3408
Ye and Houle , 1997	3414
Ye	3414
Houle , 1997	3421
Houle	3421
1997	3428
Blesch and Tuszynski , 2003	3434
Blesch and Tuszynski	3434
2003	3456
extracellular matrix components	3463
biopolymers -LRB- Novikova et al. , 2002 , 2003 ; Woerly et al. , 2004 -RRB-	3499
biopolymers	3499
Novikova	3512
et al. , 2002 , 2003 ; Woerly et al. , 2004	3521
et al.	3521
2002 , 2003 ; Woerly et al.	3529
2002 , 2003	3529
2002	3529
2003	3535
Woerly et al.	3541
Woerly	3541
et al.	3548
2004	3556
3	3564
cellular transplantation	3570
Li	3596
et al. , 1997	3599
et al.	3599
1997	3607
Xu et al. , 1997	3613
Xu	3613
et al. , 1997	3616
et al.	3616
1997	3624
Ramo ' n-Cueto et al. , 1998 , 2000	3630
Ramo ' n-Cueto et al.	3630
Ramo ' n-Cueto	3630
Ramo '	3630
et al.	3644
1998 , 2000	3652
1998	3652
2000	3658
Takami et al. , 2002	3664
Takami	3664
et al. , 2002	3671
et al.	3671
2002	3679
review , see Bunge and Pearse , 2003	3690
review	3690
see Bunge and Pearse , 2003	3698
Bunge and Pearse , 2003	3702
Bunge and Pearse	3702
2003	3720
stimulation	3735
agents	3752
the intrinsic capacity of neuronal regeneration programs	3797
the intrinsic capacity	3797
neuronal regeneration programs	3823
review , see Pearse , 2004	3859
review	3859
see Pearse , 2004	3867
Pearse , 2004	3871
Pearse	3871
2004	3879
the elevation	3896
intracellular cAMP -LRB- Neumann et al. , 2002 ; Qiu et al. , 2002 -RRB-	3913
intracellular cAMP	3913
Neumann	3932
et al. , 2002 ; Qiu et al. , 2002	3940
et al.	3940
2002 ; Qiu et al.	3948
2002	3948
Qiu et al.	3954
Qiu	3954
et al.	3958
2002	3966
manipulation	3975
the Rho pathway -LRB- Dergham et al. , 2002 ; Fournier et al. , 2003 -RRB-	3991
the Rho pathway	3991
Dergham	4008
et al. , 2002 ; Fournier et al. , 2003	4016
et al.	4016
2002 ; Fournier et al.	4024
2002	4024
Fournier et al.	4030
Fournier	4030
et al.	4039
2003	4047
treatments targeting these processes	4062
treatments	4062
these processes	4083
regeneration and functional recovery	4152
SCI	4195
the number of regenerating axons	4200
the number	4200
regenerating axons	4214
small and functional recovery modest	4246
small and functional recovery	4246
the need to overcome multiple factors that limit axon growth	4297
multiple factors that limit axon growth	4318
multiple factors	4318
axon growth	4346
it	4370
a combination of strategies	4393
a combination	4393
strategies	4410
about increased axonal growth and functional recovery	4431
about increased axonal growth	4431
functional recovery	4465
the optimal combination strategy for SCI repair	4503
the optimal combination strategy	4503
SCI repair	4540
a number of studies	4552
a number	4552
studies	4564
the additive potential of two or more therapeutic approaches	4590
the additive potential	4590
two or more therapeutic approaches	4616
Such strategies	4652
cell	4676
approaches	4695
neuroprotective agents -LRB- Pearse et al. , 2004b -RRB-	4716
neuroprotective agents	4716
Pearse	4740
et al. , 2004b	4747
et al.	4747
2004b	4755
exogenous or cellular overexpressed growth factors	4763
Xu	4815
et al. , 1995a	4818
et al.	4818
1995a	4826
Bregman et al. , 1997	4833
Bregman	4833
et al. , 1997	4841
et al.	4841
1997	4849
Menei et al. , 1998	4855
Menei	4855
et al. , 1998	4861
et al.	4861
1998	4869
Coumans et al. , 2001	4875
Coumans	4875
et al. , 2001	4883
et al.	4883
2001	4891
elevation ofcAMP	4898
Lu et al. , 2004 ; Nikulina et al. , 2004 ; Pearse et al. , 2004a	4915
Lu	4915
et al. , 2004 ; Nikulina et al. , 2004 ; Pearse et al. , 2004a	4918
et al. , 2004	4918
et al.	4918
2004	4926
Nikulina et al. , 2004	4932
Nikulina	4932
et al. , 2004	4941
et al.	4941
2004	4949
Pearse et al. , 2004a	4955
Pearse	4955
et al. , 2004a	4962
et al.	4962
2004a	4970
scar-reducing enzymes -LRB- Chau et al. , 2004 -RRB-	4981
scar-reducing enzymes	4981
Chau	5004
et al. , 2004	5009
et al.	5009
2004	5017
Combinatory pharmacological therapies	5024
Guth et al. , 1994 ; Mu et al. , 2000	5085
Guth	5085
et al. , 1994 ; Mu et al. , 2000	5090
et al. , 1994	5090
et al.	5090
1994	5098
Mu et al. , 2000	5104
Mu	5104
et al. , 2000	5107
et al.	5107
2000	5115
Schwann cell -LRB- SC -RRB- implants	5137
the addition	5178
methylprednisolone -LRB- Chen et al. , 1996 -RRB-	5194
methylprednisolone	5194
Chen	5214
et al. , 1996	5219
et al.	5219
1996	5227
neurotrophins	5234
Xu	5249
et al. , 1995a	5252
et al.	5252
1995a	5260
Menei et al. , 1998	5267
Menei	5267
et al. , 1998	5273
et al.	5273
1998	5281
Weidner et al. , 1999	5287
Weidner	5287
et al. , 1999	5295
et al.	5295
1999	5303
Bamber et al. , 2001	5309
Bamber	5309
et al. , 2001	5316
et al.	5316
2001	5324
olfactory ensheathing glia -LRB- OEG -RRB-	5331
olfactory ensheathing glia	5331
OEG	5359
Ramo ' n-Cueto et al. , 1998	5365
Ramo ' n-Cueto et al.	5365
Ramo ' n-Cueto	5365
Ramo '	5365
1998	5387
elevated cAMP -LRB- Pearse et al. , 2004a -RRB-	5397
elevated cAMP	5397
Pearse	5412
et al. , 2004a	5419
et al.	5419
2004a	5427
axonal regeneration	5457
The current study	5478
a combination of interventions	5504
a combination	5504
interventions	5521
inhibitory cues of the scar tissue -LRB- chondroitinase ABC -RRB-	5547
inhibitory cues	5547
the scar tissue -LRB- chondroitinase ABC -RRB-	5566
the scar tissue	5566
chondroitinase ABC	5583
chondroitinase	5583
ABC	5598
a growth-supportive substrate for axonal regeneration -LRB- SC bridge -RRB-	5614
a growth-supportive substrate	5614
axonal regeneration -LRB- SC bridge -RRB-	5648
axonal regeneration	5648
SC bridge	5669
regenerated axons	5693
the bridge -LRB- OEG -RRB- in adult rats	5720
the bridge -LRB- OEG -RRB-	5720
the bridge	5720
OEG	5732
adult rats	5740
complete spinal cord transection	5756
Materials and Methods Cell culture Schwann cells .	5791
Materials and Methods	5791
Materials	5791
Methods	5805
Cell culture Schwann cells	5813
Cell culture	5813
Schwann cells	5826
SCs	5841
sciatic nerves	5864
adult female Fischer rats -LRB- Harlan , Indianapolis , IN -RRB-	5882
adult female Fischer rats	5882
Morrissey	5960
et al. , 1991	5970
et al.	5970
1991	5978
Nerves	5985
small pieces	6006
culture dishes in DMEM/10 % heat-inactivated fetal bovine serum -LRB- FBS -RRB-	6033
culture dishes	6033
DMEM/10 % heat-inactivated fetal bovine serum -LRB- FBS -RRB-	6051
DMEM/10 % heat-inactivated fetal bovine serum	6051
DMEM/10 %	6051
FBS	6096
mitogens	6109
2 weeks	6125
the pieces	6134
new dishes	6165
they	6182
DMEM/10 %	6239
FBS supplemented with three	6248
FBS	6248
three	6270
two , mitogens	6289
two	6289
mitogens	6294
bovine pituitary extract	6304
2 mg/ml ; Invitrogen Corporation , Carlsbad , CA	6330
2 mg/ml	6330
Invitrogen Corporation , Carlsbad , CA	6339
forskolin -LRB- 0.8 µg/ml -RRB-	6378
forskolin	6378
0.8 µg/ml	6389
heregulin -LRB- 2.5 nM ; Genentech , San Francisco , CA -RRB-	6405
heregulin	6405
2.5 nM ; Genentech	6416
2.5 nM	6416
Genentech	6424
San Francisco , CA	6435
San Francisco	6435
CA	6450
Meijs	6479
et al. , 2004	6485
et al.	6485
2004	6493
The purity of the SCs assessed by using the S100 and Hoechst stains	6500
The purity	6500
the SCs assessed by using the S100 and Hoechst stains	6514
the SCs	6514
the S100 and Hoechst stains	6540
95 -- 98 %	6572
95	6572
98 %	6575
Olfactory ensheathing glia	6580
cultures of OEG	6624
cultures	6624
OEG	6636
the nerve fiber	6659
layer	6675
the olfactory bulb	6684
adult female Fischer rats	6706
Harlan	6733
a procedure	6747
one described previously -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	6773
one	6773
Ramo ' n-Cueto et al. , 1998	6799
Ramo ' n-Cueto et al.	6799
Ramo ' n-Cueto	6799
Ramo '	6799
1998	6821
The pia	6828
care	6852
the inclusion of non-nerve fiber layer bulb tissue	6879
the inclusion	6879
non-nerve fiber layer bulb tissue	6896
OEG	6931
the method of Ramo ' n-Cueto et al. -LRB- 1998 -RRB-	6964
the method	6964
Ramo ' n-Cueto et al. -LRB- 1998 -RRB-	6978
Ramo ' n-Cueto	6978
Ramo '	6978
et al. -LRB- 1998 -RRB-	6992
et al.	6992
1998	7000
5 d	7024
forskolin -LRB- 0.8 µg/ml -RRB- and pituitary extract -LRB- 2 mg/ml -RRB-	7031
forskolin	7031
0.8 µg/ml	7042
pituitary extract	7057
2 mg/ml	7076
DMEM/F -12	7088
10 % FBS before purification	7098
10 % FBS	7098
purification	7113
p75 immuno-panning as described previously -LRB- Takami et al. , 2002 -RRB-	7129
p75 immuno-panning	7129
Takami	7173
et al. , 2002	7180
et al.	7180
2002	7188
The OEG	7195
2 passages -LRB- at ≈ 18 d after extraction from the olfactory bulb -RRB-	7219
2 passages	7219
≈ 18 d after extraction from the olfactory bulb	7234
≈ 18 d	7234
extraction from the olfactory bulb	7246
extraction	7246
the olfactory bulb	7262
A second period in mitogens	7283
A second period	7283
mitogens	7302
confluency for transplantation	7334
confluency	7334
transplantation	7349
the purity	7375
SCs	7401
that p75 , rather than S100 ,	7412
that p75	7412
S100	7434
Hoechst nuclear staining	7454
Purity	7480
between 94 and 98 %	7503
Preparation of the cells for grafting .	7523
Preparation	7523
the cells for grafting	7538
the cells	7538
grafting	7552
SCs or OEG	7571
DMEM/F -12 medium	7600
transplantation	7625
OEG	7642
them	7673
the dishes	7683
the cells	7699
a hemocytometer	7728
SCs	7745
a 60:40 -LRB- v/v -RRB- solution	7769
DMEM/F -12 : Matrigel -LRB- BD Biosciences , San Jose , CA -RRB-	7795
DMEM/F -12	7795
Matrigel	7805
BD Biosciences	7815
San Jose	7831
CA	7841
Each animal	7874
a total of 5 x 106 SCs for transplantation	7895
a total of 5	7895
a total	7895
5	7906
106 SCs for transplantation	7910
106 SCs	7910
transplantation	7922
OEG	7939
aliquots of 4 µl of DMEM/F -12 medium	7963
aliquots	7963
4 µl of DMEM/F -12 medium	7975
4 µl	7975
DMEM/F -12 medium	7983
4 x 105 cells immediately	8011
4 x	8011
105 cells	8015
spinal cord injection	8044
Surgical procedures The experiments	8067
Surgical procedures	8067
The experiments	8087
adult female Fischer rats	8124
165	8151
180 g ; Charles River Laboratories , Wilmington , MA	8156
180 g	8156
Charles River Laboratories , Wilmington , MA	8163
Charles River Laboratories	8163
Wilmington , MA	8191
All rats	8208
a 12 h light/dark cycle	8230
water and food ad libitum.Acomplete injury model	8267
water	8267
food ad libitum.Acomplete injury model	8277
regeneration of axons	8329
regeneration	8329
axons	8345
The experiment	8385
the animal welfare committee	8416
the University of Alberta	8448
the University	8448
Alberta	8466
arrival	8481
the rats	8490
2 weeks	8516
Ensure	8545
complete meal replacement	8553
Ross products division ; Abbott Laboratories	8580
Ross products division	8580
Abbott Laboratories	8604
Irving , TX	8625
a syringe	8642
the different treatment combinations	8657
the rats	8695
three experimental groups	8722
control group	8753
transection and Matrigel-only bridge	8772
n	8810
8	8814
transection	8822
SCs and Matrigel bridge	8839
SCs	8839
Matrigel bridge	8847
rostrocaudal OEG grafts	8864
pump delivery of galactosidase and mouse IgG	8893
pump delivery	8893
galactosidase and mouse IgG	8910
as graft-only group ; n = 7	8951
as graft-only group	8951
n = 7	8972
n	8972
7	8976
-LRB- 3 -RRB- transection with SC	8984
transection	8988
SC	9005
Matrigel bridge , rostrocaudal OEG grafts	9008
Matrigel bridge	9008
rostrocaudal OEG grafts	9025
pump delivery of chondroitinase ABC	9054
pump delivery	9054
chondroitinase ABC	9071
mouse IgG -LRB- referred to as cABC group ; n = 5 -RRB-	9094
mouse IgG	9094
cABC group ; n = 5	9120
cABC group	9120
n = 5	9132
n	9132
5	9134
The treatments	9138
Fig. 1	9172
The IgG	9180
the experiment	9210
a control for an additional treatment group , which is not reported here	9228
a control	9228
an additional treatment group , which is not reported here	9242
an additional treatment group	9242
Spinal cord transection and Schwann cell grafting Animals	9301
Spinal cord transection and Schwann cell	9301
Animals	9351
a subcutaneous injection	9382
Hypnorm	9410
120 µl per 200 g body weight ; Janssen Pharmaceutics , Beerse , Belgium	9419
120 µl	9419
200 g body weight ; Janssen Pharmaceutics , Beerse , Belgium	9430
200 g body weight	9430
Janssen Pharmaceutics , Beerse , Belgium	9449
Janssen Pharmaceutics	9449
Beerse , Belgium	9472
Midazolam	9493
0.75 mg in 150 µl/200 g body weight	9504
0.75 mg in 150 µl/200	9504
0.75 mg	9504
150 µl/200	9515
g body weight	9526
750 µl total volume	9541
H2O ; Sabex , Boucherville , Quebec , Canada	9574
H2O	9574
Sabex , Boucherville , Quebec , Canada	9579
Eye lubricant	9617
Tears Naturale ; Alcon , Mississauga , Ontario , Canada	9632
Tears Naturale	9632
Alcon , Mississauga , Ontario , Canada	9648
the eyes	9708
dehydration	9722
a laminectomy at the T 7.5 -- 9 vertebral level	9741
a laminectomy at the T 7.5	9741
a laminectomy	9741
the T 7.5	9758
9 vertebral level	9768
the meningeal membranes	9787
the dura mater	9835
the spinal cord	9851
a 4 mmregion of spinal cord encompassing T8	9898
a 4 mmregion	9898
spinal cord encompassing T8	9914
spinal cord	9914
T8	9939
The rostral and caudal stumps	9955
The rostral	9955
caudal stumps	9971
removal of the spinal cord segment	10003
removal	10003
the spinal cord segment	10014
complete discontinuity	10048
All spinal roots visible in the injury gap	10072
All spinal roots	10072
the injury gap	10100
bleeding	10133
Gelfoam -LRB- Upjohn , Kalamazoo , MI -RRB-	10160
Gelfoam	10160
Upjohn	10169
Kalamazoo	10177
MI	10188
≈ 2 x 105 OEG	10205
≈ 2	10205
105 OEG	10210
a glass pipette	10234
a tip diameter of 150	10255
a tip diameter	10255
150	10273
200 µm	10277
a 5 µl	10297
Hamilton syringe -LRB- Hamilton , Reno , NV -RRB- attached to a micromanipulator	10304
Hamilton syringe	10304
Hamilton	10322
Reno	10332
NV	10338
a micromanipulator	10354
The cells	10374
two injection sites at the rostral	10404
two injection sites	10404
the rostral	10427
the caudal stump , ≈ 2 mm from the lesion ,	10450
the caudal stump	10450
≈ 2 mm from the lesion	10468
≈ 2 mm	10468
the lesion	10479
300 µm lateral to the midline	10494
300 µm lateral	10494
the midline	10512
a depth of 800 µm	10532
a depth	10532
800 µm	10543
A volume of 1 µl containing ≈ 105 OEG in DMEM/F -12	10551
A volume	10551
1 µl containing ≈ 105 OEG in DMEM/F -12	10563
1 µl	10563
≈ 105 OEG	10579
DMEM/F -12	10591
each site	10618
the rostral cord stump	10635
2 mm	10671
guidance channel -LRB- 2.6 mm inner diameter , 3.0 mm outer diameter ;	10767
guidance channel	10767
2.6 mm inner diameter , 3.0 mm outer diameter	10785
2.6 mm	10785
inner diameter , 3.0 mm outer diameter	10792
inner diameter	10792
3.0 mm outer diameter	10808
3.0 mm	10808
outer diameter	10815
T. Hazlett , CytoTherapeutics , Providence , RI -RRB- , previously cleaned	10843
T. Hazlett	10843
CytoTherapeutics	10855
Providence	10873
RI	10885
sterilized -LRB- Aebischer et al. , 1988 -RRB-	10913
sterilized	10913
Aebischer	10925
et al. , 1988	10935
et al.	10935
1988	10943
The channel	10950
1 mm	10982
the insertion of the caudal stump	10997
the insertion	10997
the caudal stump	11014
the channel	11039
two small windows	11060
the dorsal surface of the channel	11105
the dorsal surface	11105
the channel	11127
implantation	11146
30 µl	11167
SCs	11176
a 60:40 -LRB- v/v -RRB- solution of DMEM/F -12	11193
a 60:40 -LRB- v/v -RRB- solution	11193
DMEM/F -12	11219
Matrigel	11229
the channel	11253
The windows	11266
Matrigel	11311
surgery	11325
5 min	11348
semisolidification of the Matrigel-SC cable	11363
semisolidification	11363
the Matrigel-SC cable	11385
37 °C	11410
addition to the drug delivery using pumps -LRB- see below -RRB-	11419
addition	11419
the drug delivery using pumps -LRB- see below -RRB-	11431
the drug delivery	11431
pumps	11455
the lesion	11498
the wound	11510
chondroitinase or vehicle	11536
The surgeon	11563
both kinds of treatments	11591
both kinds	11591
treatments	11605
cABC delivery A double catheter	11617
cABC delivery A	11617
double catheter	11633
two fine catheters -LRB- Re - CathCo , Allison Park , PA -RRB-	11676
two fine catheters	11676
Re	11696
CathCo , Allison Park , PA	11700
CathCo	11700
Allison Park	11708
PA	11722
a connecting tube	11731
the minipumps -LRB- model 2002 ; Alzet , Cupertino , CA -RRB-	11754
the minipumps	11754
model 2002 ; Alzet , Cupertino , CA	11769
model 2002	11769
Alzet , Cupertino , CA	11781
The ends	11804
deliv	11833
ery	11840
the rostral	11847
caudal spinal cord	11863
the guidance channel	11890
the delivery	11926
the chondroitinase -LRB- cABC ; Seikagaku America , East Falmouth , MA -RRB-	11942
the chondroitinase	11942
cABC ; Seikagaku America	11962
cABC	11962
Seikagaku America	11968
East Falmouth , MA	11987
East Falmouth	11987
MA	12002
the sites of scarring at the SC bridge	12009
the sites	12009
scarring at the SC bridge	12022
scarring	12022
the SC bridge	12034
host spinal cord interfaces	12049
The tubing	12078
sutures	12104
the caudal musculature	12115
The connected minipump	12139
sterile 0.9 % NaCl	12172
the catheters	12198
the intervals between cABC injections	12225
the intervals	12225
cABC injections	12247
2µl of 10µg/ml cABC	12264
2µl	12264
10µg/ml cABC	12271
Injections	12286
every other day for 4 weeks	12312
every other day	12312
4 weeks	12332
short isoflurane anesthesia	12346
Pumps	12375
skin pouches	12398
the back of the rats	12414
the back	12414
the rats	12426
position	12447
sutures	12461
the overlying muscles	12479
layers	12517
the skin	12529
wound clips	12554
Antibody delivery A fine -LRB- 32 gauge -RRB- intrathecal catheter	12567
Antibody delivery A fine	12567
32 gauge	12593
intrathecal catheter	12603
ReCathCo	12625
the lumbar level to its delivery site	12664
the lumbar level	12664
its delivery site	12684
the caudal SC bridge / host spinal cord interface	12705
the caudal SC bridge	12705
host spinal cord interface	12727
host	12727
spinal cord interface	12732
The catheter	12755
the antibody -LRB- model 2002 ; Alzet -RRB-	12777
the antibody	12777
model 2002 ; Alzet	12791
model 2002	12791
Alzet	12803
the injury site	12813
4 weeks	12833
Pumps	12842
antibody -LRB- IgG -RRB-	12858
antibody	12858
IgG	12868
a concentration of 3 mg/ml	12876
a concentration	12876
3 mg/ml	12895
PBS	12906
the delivery rate of the pumps	12915
the delivery rate	12915
the pumps	12936
0.6 µl/h -LRB- ≈ 1.8 µg/h -RRB-	12950
0.6 µl/h	12950
≈ 1.8 µg/h	12960
≈	12960
1.8 µg/h	12961
surgery	12978
the animals	12987
a thermostatically regulated heating pad	13012
The analgesic Buprenex	13077
buprenorphine ; Reckitt and Colman	13101
buprenorphine	13101
Reckitt and Colman	13116
Richmond , VA	13136
Richmond	13136
VA	13146
0.03 mg/kg	13183
operation and every 8 h	13213
operation	13213
every 8 h	13227
74 h.	13241
Ringer 's solution -LRB- 4 ml -RRB-	13247
Ringer 's solution	13247
Ringer 's	13247
4 ml	13266
the first week	13307
later stages	13329
animals	13345
signs of dehydration	13360
signs	13360
dehydration	13369
The antibiotic	13382
cefazolin -LRB- 5 mg/kg , s.c. ; Novopharm , Toronto , Ontario , Canada -RRB-	13398
cefazolin	13398
5 mg/kg , s.c. ; Novopharm , Toronto , Ontario , Canada	13409
5 mg/kg	13409
s.c. ; Novopharm , Toronto , Ontario , Canada	13418
s.c.	13418
Novopharm , Toronto , Ontario , Canada	13424
each day	13483
4 d	13496
1 d before surgery	13512
1 d	13512
surgery	13523
Bladders	13532
three times per day	13556
three times	13556
day	13572
the voiding reflex of the bladder was reestablished	13582
the voiding	13582
reflex of the bladder	13594
reflex	13594
the bladder	13604
2 weeks after injury	13639
2 weeks	13639
injury	13653
up to 1 ml of Ensure -LRB- chocolate or vanilla -RRB-	13661
up to 1 ml of Ensure	13661
1	13667
ml	13669
Ensure	13675
chocolate or vanilla	13683
chocolate	13683
vanilla	13696
each rat	13716
twice each day	13725
2 weeks	13747
pumps	13756
isoflurane anesthesia	13783
4 weeks	13813
pumps and catheters	13822
chondroitin sulfate digestions	13867
cABC	13918
chondroitin sulfate	13932
the host cord/SC graft interface	13955
three monoclonal antibodies	13989
either intact or digested chondroitin sulfate	14032
immunochemical staining	14092
alternative spinal cord sections	14119
2 week cABC-treated -LRB- n = 2 -RRB- or galactosidase-treated grafted animals	14155
2 week	14155
n = 2	14176
n	14176
= 2	14178
n	14225
3	14229
One antibody , 2B6 -LRB- 1:150 ; Seikagaku America -RRB- ,	14233
One antibody	14233
2B6 -LRB- 1:150 ; Seikagaku America -RRB-	14247
2B6	14247
1:150 ; Seikagaku America	14252
1:150	14252
Seikagaku America	14259
an epitope created after cABC degradation of chondroitin-4 sulfate	14290
an epitope	14290
cABC degradation of chondroitin-4 sulfate	14315
cABC degradation	14315
chondroitin-4 sulfate	14335
the intact form -LRB- Moon et al. , 2001 -RRB-	14379
the intact form	14379
Moon	14396
et al. , 2001	14401
et al.	14401
2001	14409
The other antibodies used	14416
The other antibodies	14416
CS-56	14447
1:500 ; Sigma-Aldrich	14454
1:500	14454
Sigma-Aldrich	14461
St. Louis , MO	14476
St. Louis	14476
MO	14487
an epitope	14509
various intact chondroitin sulfate glycosaminoglycan chains	14531
1D1	14596
1:200	14601
Developmental Studies Hybridoma Bank , University of Iowa , Iowa City , IA	14608
Developmental Studies Hybridoma Bank , University	14608
Iowa , Iowa City , IA	14660
the CSPG core protein of neurocan -LRB- Moon et al. , 2002 -RRB-	14699
the CSPG core protein	14699
neurocan -LRB- Moon et al. , 2002 -RRB-	14724
neurocan	14724
Moon	14734
et al. , 2002	14739
et al.	14739
2002	14747
An increase of 2B6	14754
An increase	14754
2B6	14769
a reduction	14777
the amount of either CS-56 or 1D1 immunoreactivity	14792
the amount	14792
either CS-56 or 1D1 immunoreactivity	14806
CS-56	14813
1D1 immunoreactivity	14822
the interface	14846
cABC efficacy	14875
changes	14901
immunoreactivity intensity	14912
2B6 , CS-56 , and 1D1 at the caudal host cord/SC graft interface	14942
2B6 , CS-56 , and 1D1	14942
the caudal host cord/SC graft interface	14965
40 µm sagittal sections at every 200µm -LRB- 10 -- 12 sections/animal -RRB-	15006
40 µm sagittal sections	15006
every 200µm -LRB- 10 -- 12 sections/animal -RRB-	15033
every 200µm	15033
10 -- 12 sections/animal	15046
10	15046
12 sections/animal	15049
computer-assisted microscopy and MetaMorph software	15090
Universal Imaging Corporation , West Chester , PA	15143
Universal Imaging Corporation	15143
West Chester	15174
PA	15188
each section	15196
images	15210
an 800x800 µm area	15230
both SC and the contiguous host cord region of the caudal interface	15269
both SC	15269
the contiguous host cord region of the caudal interface	15281
the contiguous host cord region	15281
the caudal interface	15316
a line drawn through the center of the cord	15356
a line	15356
the center of the cord	15377
the center	15377
the cord	15391
Immunoreactivity intensity	15416
arbitrary units ; higher value indicating greater staining	15444
arbitrary units	15444
higher value indicating greater staining	15461
higher value	15461
greater staining	15485
each antibody at the caudal interface	15507
each antibody	15507
the caudal interface	15524
animal	15564
intensity values	15593
all sections examined	15617
all sections	15617
Testing locomotor recovery Recovery of hindlimb stepping movements	15640
Testing locomotor recovery Recovery	15640
hindlimb	15679
movements	15697
several locomotor tests	15727
recovery	15772
increased excitability of spinal networks	15801
increased excitability	15801
spinal networks	15827
partial reestablishment of descending control	15849
partial reestablishment	15849
descending control	15876
Basso , Beattie , and Bresnahan	15896
The open-field locomotor score -LRB- Basso et al. , 1995 -RRB-	15933
The open-field locomotor score	15933
Basso	15965
et al. , 1995	15971
et al.	15971
1995	15979
two blinded observers	16003
testing	16033
bladders	16042
spontaneous bladder contraction	16075
hindlimb activity	16125
The rats	16144
a transparent Plexiglas box -LRB- 30 x 90 x 120 cm -RRB-	16168
a transparent Plexiglas box	16168
30	16197
x 90 x 120 cm	16200
90	16202
120 cm	16207
a smooth floor	16220
4 min	16257
Hindlimb movements	16264
contact with experimenters	16301
contact	16301
experimenters	16314
the open-field activity	16353
the animals	16378
a digital camera	16421
a shutter speed of 1/250 s for additional analysis of forelimb/hindlimb coupling	16444
a shutter speed	16444
1/250 s for additional analysis of forelimb/hindlimb coupling	16463
1/250 s	16463
additional analysis of forelimb/hindlimb coupling	16475
additional analysis	16475
forelimb/hindlimb coupling	16498
Forelimb/hindlimb coupling .	16526
Forelimb/hindlimb	16526
coupling	16544
This analysis	16554
valuable information	16573
the Basso , Beattie , and Bresnahan -LRB- BBB -RRB- score	16597
the Basso	16597
Beattie	16608
Bresnahan -LRB- BBB -RRB- score	16621
both the frequency of hindlimb activity and the coordination with the forelimb	16652
the frequency of hindlimb activity	16657
the frequency	16657
hindlimb activity	16674
the coordination with the forelimb	16696
the coordination	16696
the forelimb	16718
walking sequences	16738
account	16771
hindlimb coupling	16802
the order of steps made by an ipsilateral forelimb / hindlimb pair was recorded	16821
the order	16821
steps made by an ipsilateral forelimb / hindlimb pair was recorded	16834
steps	16834
an ipsilateral forelimb / hindlimb pair was recorded	16848
an ipsilateral forelimb	16848
hindlimb pair	16873
Percentage scores of forelimb/hindlimb coupling	16901
Percentage scores	16901
forelimb/hindlimb coupling	16922
the number of correct couplings	16977
the number	16977
correct couplings	16991
a forelimb step	17019
a hindlimb step , or vice	17051
a hindlimb step	17051
vice	17071
the total number	17086
couplings	17106
the sequence -LRB- the number of steps in the sequence minus one -RRB-	17119
the sequence	17119
the number of steps in the sequence minus one	17133
the number	17133
steps in the sequence minus one	17147
steps	17147
the sequence minus one	17156
this analysis	17185
five video sequences per animal , with a minimum of six forelimb steps ,	17200
five video sequences	17200
animal	17225
a minimum of six forelimb steps	17238
a minimum	17238
six forelimb steps	17251
Role of sensory feedback on hindlimb movement .	17284
Role	17284
sensory feedback	17292
hindlimb movement	17312
A major issue	17331
testing locomotor recovery	17350
whether hindlimb movements	17391
volitional drive	17435
sensory feedback	17458
the hindlimbs	17480
the ground	17517
this question	17544
we	17559
open-field locomotion	17569
different surfaces	17594
addition to the smooth Plexiglas surface in the open field described above	17617
addition	17617
the smooth Plexiglas surface in the open field described above	17629
the smooth Plexiglas surface	17629
the open field described above	17661
the open field	17661
we	17693
a slippery surface and a rough surface	17701
a slippery surface	17701
a rough surface	17724
These tests	17741
the literature	17792
locomotion	17816
a slippery surface	17830
we	17850
a Plexiglas runway -LRB- 80 x 10 cm , with 10 cm high walls -RRB-	17858
a Plexiglas runway	17858
80 x 10 cm	17878
80	17878
10 cm	17883
10 cm high walls	17895
its walking surface covered by a thin layer of paraffin oil	17918
its walking surface	17918
a thin layer of paraffin oil	17949
a thin layer	17949
paraffin oil	17965
this surface	17982
forward propulsion	17996
stationary walking	18031
rats	18056
movements	18080
their forelimbs	18095
the amount of sensory feedback to the hindlimbs from passive sliding	18123
the amount	18123
sensory feedback to the hindlimbs from passive sliding	18137
sensory feedback	18137
the hindlimbs from passive sliding	18157
the hindlimbs	18157
passive sliding	18176
passive	18176
Events where forelimb and hindlimb movements occurred in a stepping sequence	18205
Events	18205
forelimb and hindlimb movements	18218
a stepping sequence	18262
The test	18295
9 weeks after transection and only in animals with BBB scores of 6	18326
9 weeks	18326
transection	18340
animals with BBB scores of 6	18364
animals	18364
BBB scores of 6	18377
BBB scores	18377
6	18391
the influence of increased sensory feedback	18413
the influence	18413
increased sensory feedback	18430
the rats	18458
a rough carpet	18482
the forelimb/hindlimb couplings	18502
open-field locomotion	18568
This test	18591
9 weeks	18623
transection	18637
all animals	18650
the carpet	18677
Sensory testing Each rat	18689
Sensory testing	18689
Each rat	18705
a towel	18729
its covered head	18756
the hindlimbs	18796
the rats	18836
they	18884
five different locations	18908
dermatomes	18936
their ascending projections	18957
the tail , skin	19000
the tail	19000
skin	19010
the femur on both hindlegs , and the dorsal surfaces of both hindpaws	19021
the femur on both hindlegs	19021
the femur	19021
both hindlegs	19034
the dorsal surfaces of both hindpaws	19053
the dorsal surfaces	19053
both hindpaws	19076
a set of von Frey hairs -LRB- Stoelting , Wood Dale , IL -RRB-	19112
a set	19112
von Frey hairs -LRB- Stoelting , Wood Dale , IL -RRB-	19121
von Frey hairs	19121
Stoelting	19137
Wood Dale	19148
IL	19159
The von Frey hair	19164
the skin and pressure applied -LRB- target force , 0.04 -- 1 g -RRB-	19196
the skin and pressure	19196
target	19227
force , 0.04 -- 1 g	19234
force	19234
0.04	19241
1 g	19246
it	19260
The stimulation	19313
a low intensity -LRB- small hair diameter ; 0.04 g target force -RRB-	19342
a low intensity	19342
small hair diameter ; 0.04 g target force	19359
small hair diameter	19359
0.04 g target force	19380
three times	19418
no	19434
response	19444
the next thicker hair	19467
The lowest stimulation intensity to produce a response	19499
The lowest stimulation intensity	19499
a response	19543
three times	19567
the sensation threshold	19586
Repeated stimulations of any given spot	19624
Repeated stimulations	19624
any given spot	19649
at least 2 min	19682
desensitization	19706
Tracing and histology	19723
10 weeks	19748
injury , the corticospinal tract -LRB- CST -RRB- and reticulospinal tract	19763
injury	19763
the corticospinal tract -LRB- CST -RRB-	19771
reticulospinal tract	19805
RtST	19827
Hypnorm/Midazolam anesthesia -LRB- as described above -RRB-	19864
Hypnorm/Midazolam anesthesia	19864
the CST	19919
2 µl	19936
biotinylated dextran amine -LRB- BDA -RRB-	19944
biotinylated dextran amine	19944
BDA	19972
molecular weight -LRB- MW -RRB- , 10,000	19978
molecular weight	19978
MW	19996
10,000	20001
D-1956 , 10 % in 0.01 M PBS	20009
D-1956	20009
10 % in 0.01 M PBS	20017
10 %	20017
0.01 M PBS	20024
Molecular Probes , Eugene	20036
Molecular Probes	20036
Eugene	20054
OR	20062
four sites	20085
the sensorimotor cortex using a Hamilton syringe as described previously	20099
the sensorimotor cortex	20099
a Hamilton syringe	20129
Fouad	20173
et al. , 2001	20179
et al.	20179
2001	20187
the RtST	20209
a long-necked glass microelectrode	20219
a Hamilton syringe	20267
the giant nucleus of the reticular formation	20318
the giant nucleus	20318
the reticular formation	20339
Paxinos and Watson , 1986	20381
Paxinos and Watson	20381
1986	20401
A volume of 0.35 µl 5 % Micro Ruby	20408
A volume of 0.35 µl 5 %	20408
A volume	20408
0.35 µl 5 %	20420
0.35 µl	20420
Micro Ruby	20431
dextran , tetramethylrhodamine , and biotin ; 3000 MW ; Molecular Probes	20443
dextran , tetramethylrhodamine , and biotin	20443
3000 MW ; Molecular Probes	20486
3000 MW	20486
Molecular Probes	20495
a period of 5 min	20538
a period	20538
5 min	20550
Two weeks after the tracing , the animals	20557
Two weeks	20557
the tracing , the animals	20573
the tracing	20573
the animals	20586
pentobarbital -LRB- Euthanyl , Bimeda-MTC ; 70 mg/100 mg body weight -RRB-	20615
pentobarbital	20615
Euthanyl , Bimeda-MTC ; 70 mg/100 mg body weight	20630
Euthanyl , Bimeda-MTC	20630
70 mg/100 mg body weight	20652
70 mg/100	20652
mg body weight	20662
phosphate-buffered 4 % paraformaldehyde -LRB- 0.1 M , pH7 .4 -RRB-	20711
phosphate-buffered 4 % paraformaldehyde	20711
0.1 M , pH7 .4	20751
0.1 M	20751
pH7 .4	20758
Takami	20766
et al. , 2002	20773
et al.	20773
2002	20781
The spinal cord and brain	20788
The spinal cord	20788
brain	20808
overnight in the same fixative	20841
overnight	20841
the same fixative	20854
4 °C	20875
The spinal cords	20880
a surgical microscope for continuity of the bridge and the spinal cord	20917
a surgical microscope	20917
continuity of the bridge and the spinal cord	20943
continuity	20943
the bridge and the spinal cord	20957
the bridge	20957
the spinal cord	20972
A 1-mm-thick transverse slice	21006
the middle of the SC bridge	21051
the middle	21051
the SC bridge	21065
2 % glutaraldehyde	21093
100 mM sucrose	21116
phosphate buffer -LRB- PB ; 0.05 M , pH7 .4 -RRB- for at least 24 h	21134
phosphate buffer -LRB- PB ; 0.05 M , pH7 .4 -RRB-	21134
phosphate buffer	21134
PB ; 0.05 M , pH7 .4	21152
PB	21152
0.05 M , pH7 .4	21156
0.05 M	21156
pH7 .4	21164
at least 24 h	21175
4 °C	21192
This tissue	21197
further fixed in 1 % buffered osmium tetroxide for 2	21218
further	21218
1 % buffered osmium tetroxide for 2	21235
1 %	21235
osmium tetroxide for 2	21247
osmium tetroxide	21247
2	21268
16 h , dehydrated ,	21270
16 h	21270
Epon-Araldite -LRB- Electron Microscopy Sciences , Fort Washington , PA -RRB-	21300
Epon-Araldite	21300
Electron Microscopy Sciences , Fort Washington , PA	21315
Electron Microscopy Sciences	21315
Fort Washington	21345
PA	21362
semithin sections -LRB- 1 µm -RRB-	21391
semithin sections	21391
1 µm	21410
These sections	21417
a 1 % toluidine blue -- 1 % methylene blue --	21450
a 1 % toluidine blue	21450
1 % methylene blue	21470
1 % sodium borate solution	21488
1 %	21488
sodium borate solution	21491
SC bridge histology	21525
the number of myelinated axons and blood vessels	21562
the number	21562
myelinated axons and blood vessels	21576
The remaining SC bridge and adjacent rostral and caudal spinal cord and brain	21620
The remaining SC bridge	21620
adjacent rostral and caudal spinal cord	21648
brain	21692
30 % sucrose	21720
PB -LRB- 0.1 M , pH 7.4 -RRB-	21735
PB	21735
0.1 M	21739
pH 7.4	21746
at least 24 h	21758
Tissue-Tek OCT compound	21783
Sakura Finetek	21808
Torrance	21824
CA	21834
30-µm-thick sagittal sections	21852
Efficacy of the tracing	21883
Efficacy	21883
the tracing	21895
cervical cord sections	21924
Total numbers of myelinated axons and blood vessels	21948
Total numbers	21948
myelinated axons and blood vessels	21965
Xu et al. , 1995b	22038
Xu	22038
et al.	22041
1995b	22049
1-µm-thick transverse plastic sections	22078
three sections	22118
a 1 mm slice from the center of the SC bridge ; n = 6	22138
a 1 mm slice	22138
the center of the SC bridge ; n = 6	22156
the center of the SC bridge	22156
the center	22156
the SC bridge	22170
n = 6	22185
n	22185
6	22189
group	22195
the bridge area	22203
a fractionator grid	22255
630X magnification	22278
optical fractionator method ; West and Collins , 1989	22298
optical fractionator method	22298
West and Collins , 1989	22327
West and Collins	22327
1989	22345
Every blood vessel	22352
every myelinated axon present within each grid square	22375
every myelinated axon	22375
each grid square	22412
surface area , 0.028 mm2	22430
surface area	22430
0.028 mm2	22444
Immunohistochemistry The sections chosen for evaluation	22468
Immunohistochemistry	22468
The sections	22489
evaluation	22513
a second time on the slides	22539
a second time	22539
the slides	22556
4 % paraformaldehyde , 0.1 % glutaraldehyde , and 0.1 % picric acid	22572
4 % paraformaldehyde	22572
0.1 % glutaraldehyde	22593
0.1 % picric acid	22618
20 min	22639
0.1 M PB three times	22665
0.1 M PB	22665
three times	22674
A quenching step	22687
the sections	22725
10 min	22742
50 % EtOH plus 0.3 % H2O2 , followed by two washing cycles in PB for 10 min	22752
50 % EtOH	22752
0.3 % H2O2 , followed by two washing cycles in PB for 10 min	22766
0.3 % H2O2	22766
two	22789
cycles	22801
PB for 10 min	22811
PB	22811
10 min	22818
Blocking	22826
0.4 % NaBH4 for 10 min	22854
0.4 % NaBH4	22854
10 min	22869
the slides	22891
PB three times for 20 min	22905
PB	22905
three times	22908
20 min	22924
they	22932
0.1 M citrate buffer , pH 4.5 ,	22957
0.1 M citrate buffer	22957
pH 4.5	22979
4 °C	23000
The next day	23005
the slides	23019
room temperature	23045
1 min	23081
600 W , followed by two cycles of 30 s at 600	23090
600 W	23090
two cycles of 30 s at 600	23109
two cycles	23109
30 s at 600	23123
30 s	23123
600	23131
Watts in a separate glass container in 200 ml of H2O	23135
Watts	23135
a separate glass container in 200 ml of H2O	23144
a separate glass container	23144
200 ml of H2O	23174
200 ml	23174
H2O	23184
Slides	23189
30 min	23218
1 %	23258
Top Block gelatin	23261
Juro Supply	23280
Lucerne	23293
Switzerland	23302
20 min -LSB- 200 mg of Top Block in 0.3 % Tris-buffered saline with Triton X-100	23319
20 min	23319
200 mg of Top Block in 0.3 % Tris-buffered saline with Triton X-100	23327
200 mg	23327
Top Block in 0.3 % Tris-buffered saline with Triton X-100	23337
Top Block	23337
0.3 % Tris-buffered saline with Triton X-100	23350
0.3 % Tris-buffered saline	23350
Triton X-100	23381
TBS-TX	23395
The 5-HT antibody -LRB- DiaSorin , Stillwater , MN -RRB-	23405
The 5-HT antibody	23405
DiaSorin	23424
Stillwater	23434
MN	23446
a dilution of 1:8000	23463
a dilution	23463
1:8000	23477
4 % normal goat serum -LRB- NGS -RRB-	23495
4 % normal goat serum	23495
NGS	23517
the slides	23534
4 °C	23558
Slides	23563
PB for 10 min	23591
PB	23591
10 min	23598
the second	23612
goat	23636
anti rabbit antibody -LRB- 1:300 in 0.3 % TBS-TX plus 2 % NGS -RRB-	23641
anti rabbit antibody	23641
1:300 in 0.3 % TBS-TX plus 2 % NGS	23663
1:300	23663
0.3 % TBS-TX plus 2 % NGS	23672
0.3 % TBS-TX	23672
2 % NGS	23689
45 min at room temperature	23720
45 min	23720
room temperature	23730
Slides	23748
PBS for 10 min	23781
PBS	23781
10 min	23789
the ABC elite complex	23801
45 min	23837
three washing steps of 10 min each in PBS	23851
three	23851
steps of 10 min each	23865
steps	23865
10 min each	23874
10 min	23874
each	23881
PBS	23889
they	23894
0.05 M Tris , pH 8.0 ,	23922
0.05 M Tris	23922
pH 8.0	23935
5 min	23947
Slides	23954
50 ml of 0.05 MTris plus 25mgofDABplus 25µl of 30 % H2O2 for ≈ 1 -- 2 min	23982
50 ml of 0.05 MTris plus 25mgofDABplus 25µl of 30 % H2O2 for ≈ 1	23982
50 ml of 0.05 MTris	23982
50 ml	23982
0.05 MTris	23991
25mgofDABplus 25µl of 30 % H2O2 for ≈ 1	24006
25mgofDABplus 25µl	24006
30 % H2O2 for ≈ 1	24028
30 % H2O2	24028
≈ 1	24040
2 min	24043
The reaction	24050
ice-cold PBS	24078
two washes in PB for 10 min and one rinse in water	24104
two washes	24104
PB for 10 min and one rinse in water	24118
PB for 10 min	24118
PB	24118
10 min	24125
one rinse in water	24136
one rinse	24136
water	24149
Slides	24156
5-HT fiber counts The number of 5-HT-positive fibers caudal to the lesion site	24202
5-HT fiber	24202
The number of 5-HT-positive fibers	24220
The number	24220
5-HT-positive fibers	24234
the lesion site	24265
a light microscope	24315
bright-field illumination	24339
a final magnification of 400X	24368
a final magnification	24368
400X	24393
25 µm	24419
sagittal sections	24425
CST and RtST fibers	24465
CST	24465
RtST fibers	24473
spare sections	24493
the sections chosen for the analysis of 5-HT-positive fibers	24509
the sections	24509
the analysis of 5-HT-positive fibers	24533
the analysis	24533
5-HT-positive fibers	24549
75 µm intervals	24588
This	24605
the possibility of counting the same fiber twice	24620
the possibility	24620
the same fiber	24648
each	24673
these remaining sections -LRB- an average of ≈ 11 sections per animal -RRB-	24681
these remaining sections	24681
an average of ≈ 11 sections per animal	24707
an average	24707
≈ 11 sections per animal	24721
≈ 11 sections	24721
animal	24738
all fibers in the caudal spinal cord with a length of > 100 µm	24747
all fibers	24747
the caudal spinal cord with a length of > 100 µm	24761
the caudal spinal cord	24761
a length of > 100 µm	24789
a length	24789
> 100 µm	24801
>	24801
100 µm	24802
Corticospinal and reticulospinal tract staining Sections	24823
Corticospinal	24823
reticulospinal tract staining Sections	24841
a fluorescent microscope	24906
labeling	24941
Micro Ruby	24955
all animals	24970
fibers	24983
rostral	25004
the lesions	25015
some cases	25035
the bridge	25050
Sections	25062
avidin-HRP	25096
ABC Elite	25108
Vector Laboratories , Burlingame , CA	25119
Vector Laboratories	25119
Burlingame , CA	25140
a nickel-enhanced diaminobenzidine HRP reaction	25168
the visualization of the BDA tracer	25220
the visualization	25220
the BDA tracer	25241
a semifree-floating technique	25260
Herzog and Brosamle	25315
1997	25336
both CST and RtST fibers	25351
both CST	25351
RtST fibers	25364
the caudal end of the bridge	25391
the caudal end	25391
the bridge	25409
the caudal stump of the spinal cord	25426
the caudal stump	25426
the spinal cord	25446
no additional analysis	25463
Statistics	25501
statistical analysis	25519
exclusion criteria	25541
an attempt	25576
the variability in the groups	25597
the variability	25597
the groups	25616
animals	25628
a spinal cord stump -LRB- rostral or caudal -RRB-	25645
a spinal cord stump	25645
rostral or caudal	25666
rostral	25666
caudal	25677
the channel	25703
the injection	25719
the OEG	25736
inflammation	25752
a lesion that was larger than 50 % of the spinal cord	25782
a lesion	25782
50 % of the spinal cord	25812
50 %	25812
the spinal cord	25819
Statistical comparisons	25836
GraphPad Prism	25881
Comparisons between the treatment groups	25897
Comparisons	25897
the treatment groups	25917
the Mann -- Whitney U test	25954
the Mann	25954
Whitney U test	25964
Whitney U	25964
test	25974
Differences of p 0.05	25980
Differences	25980
p 0.05	25995
p 0.01	26031
Errors	26074
SEM	26094
Results Figure 1 .	26100
Results	26100
Figure 1	26108
Experimental design	26118
the cell grafting and cABC treatment	26142
the removal of the thoracic 8 segment of the spinal cord	26185
the removal	26185
the thoracic 8 segment of the spinal cord	26200
the thoracic 8 segment	26200
8	26213
the spinal cord	26226
Figure 2 .	26244
Figure	26244
2	26251
Effectiveness of cABC application	26254
Effectiveness	26254
cABC application	26271
the use of antibodies against either intact -LRB- 1D1 , CS-56 -RRB-	26307
the use	26307
antibodies against either intact -LRB- 1D1 , CS-56 -RRB-	26318
antibodies	26318
intact	26344
1D1 , CS-56	26352
1D1	26352
CS-56	26357
2B6	26377
chondroitin sulfate	26382
p < 0.05 .	26404
p	26404
< 0.05 .	26405
<	26405
0.05 .	26406
Figure 3 .	26413
Figure	26413
3	26420
Comparison	26423
the open-field locomotion scores between the different treatment groups	26437
the open-field locomotion scores	26437
the different treatment groups	26478
the BBB score -LRB- A -RRB-	26525
the BBB score	26525
A	26541
the percentage of successful forelimb / hindlimb coupling -LRB- B -RRB-	26557
the percentage	26557
successful forelimb / hindlimb coupling -LRB- B -RRB-	26575
successful forelimb / hindlimb coupling	26575
successful forelimb	26575
hindlimb coupling	26596
B	26616
C , The time course of recovery	26620
C	26620
The time course of recovery	26623
The time course	26623
recovery	26642
treatment-induced benefits	26657
8 weeks	26712
surgery	26726
The dots	26735
the scores of single animals	26754
the scores	26754
single animals	26768
p < 0.05 , ** p < 0.01 .	26785
p	26785
< 0.05 , ** p < 0.01 .	26786
<	26786
0.05 , ** p < 0.01 .	26787
0.05	26787
p < 0.01 .	26795
p	26795
< 0.01 .	26796
<	26796
0.01 .	26797
Figure 4 .	26804
Figure	26804
4	26811
Video sequence from a rat	26814
Video sequence	26814
a rat	26834
OEG and Schwann cell grafts	26853
cABC	26897
the range of leg motion	26908
the range	26908
leg motion	26921
the alternation between the forelimb and hindlimb movements	26943
the alternation	26943
the forelimb and hindlimb movements	26967
The panels	27004
rows	27032
right	27050
Figure 5 .	27058
Figure	27058
5	27065
Sensory testing using von Frey hairs at the base of the tail	27068
Sensory testing	27068
von Frey hairs at the base of the tail	27090
von Frey hairs	27090
the base of the tail	27108
the base	27108
the tail	27120
increased responsiveness in all of the treated groups	27135
increased responsiveness	27135
all of the treated groups	27163
all	27163
the treated groups	27170
p < 0.05 .	27191
p	27191
< 0.05 .	27192
<	27192
0.05 .	27193
Figure 6 .	27200
Figure	27200
6	27207
A	27210
5-HT-positive fibers	27213
the caudal spinal cord	27258
The quantification of these fibers in the caudal spinal cord	27282
The quantification	27282
these fibers in the caudal spinal cord	27304
these fibers	27304
the caudal spinal cord	27320
B	27361
C	27381
there	27384
no correlation between individual functional recovery	27394
no correlation	27394
individual functional recovery	27417
the number of 5-HT-positive fibers in the caudal spinal cord	27452
the number	27452
5-HT-positive fibers in the caudal spinal cord	27466
5-HT-positive fibers	27466
the caudal spinal cord	27490
p < 0.05 .	27515
p	27515
< 0.05 .	27516
<	27516
0.05 .	27517
Figure 7 .	27524
Figure	27524
7	27531
Significantly greater numbers of peripheral-myelinated axons -LRB- arrow -RRB-	27534
Significantly greater numbers of peripheral-myelinated axons	27534
Significantly greater numbers	27534
peripheral-myelinated axons	27567
arrow	27596
the Schwann cell bridge	27622
digestion of CSPGs with chondroitinase ABC	27652
digestion	27652
CSPGs with chondroitinase ABC	27665
CSPGs	27665
chondroitinase ABC	27676
Animals with grafts only -LRB- A -RRB- and animals with grafts and cABC	27696
Animals with grafts only -LRB- A -RRB-	27696
Animals	27696
grafts only -LRB- A -RRB-	27709
grafts only	27709
grafts	27709
A	27723
animals with grafts and cABC	27730
animals	27730
grafts and cABC	27743
B	27761
Scale bar , 150µm .	27775
Scale bar	27775
150µm	27786
Figure 8 .	27794
Figure	27794
8	27801
Counts of myelinated axons in the middle of the bridge	27804
Counts	27804
myelinated axons in the middle of the bridge	27814
myelinated axons	27814
the middle of the bridge	27834
the middle	27834
the bridge	27848
a significant -LRB- p < 0.01 -RRB- increase -LRB- A -RRB-	27866
a significant -LRB- p < 0.01 -RRB- increase	27866
p < 0.01	27882
p	27882
< 0.01	27883
<	27883
0.01	27885
A	27902
the group	27908
grafts and cABC	27923
B , The number of blood vessels in the bridge	27940
B	27940
The number of blood vessels in the bridge	27943
The number	27943
blood vessels in the bridge	27957
blood vessels	27957
the bridge	27974
the groups	28011
C	28023
There	28026
a significant correlation -LRB- r2 = 0.63 -RRB-	28036
a significant correlation	28036
r2	28063
0.63	28067
individual functional recovery	28081
the number of myelinated axons	28116
the number	28116
myelinated axons	28130
cABC	28149
chondroitin sulfate	28163
injured spinal cord	28186
Two weeks	28206
spinal cord transection	28222
tissue from three animals with grafts	28247
tissue	28247
three animals with grafts	28259
three animals	28259
grafts	28278
two	28289
cABC	28312
cABC	28351
chondroitin sulfate	28369
Three monoclonal antibodies	28390
digested or intact chondroitin sulfate	28440
an increase of 2B6	28490
an increase	28490
2B6	28505
CS-56 and 1D1 immunoreactivity at the caudal SC/spinal cord interface	28521
CS-56	28521
1D1 immunoreactivity at the caudal SC/spinal cord interface	28531
1D1 immunoreactivity	28531
the caudal SC/spinal cord interface	28555
cABC efficacy	28601
The average values of staining intensity	28616
The average values	28616
staining intensity	28638
Neurocan -LRB- 1D1 -RRB- , 89.6 ± 5.1 -LRB- SEM -RRB- and 70.3 ± 4.4 ;	28678
Neurocan -LRB- 1D1 -RRB-	28678
Neurocan	28678
1D1	28688
89.6 ± 5.1 -LRB- SEM -RRB- and 70.3 ± 4.4	28694
89.6 ± 5.1 -LRB- SEM -RRB-	28694
89.6 ±	28694
5.1 -LRB- SEM -RRB-	28699
70.3 ± 4.4	28713
70.3 ±	28713
4.4	28720
chondroitin sulfate proteoglycans -LRB- CS56 -RRB-	28729
chondroitin sulfate proteoglycans	28729
CS56	28764
69.8	28771
8.6 and 50.7	28778
± 5.3	28791
degraded chondroitin sulfate proteoglycans	28802
10 ±	28846
0.6 and 16.2	28849
± 1.1	28861
the controls and the cABC-treated rats , respectively -LRB- Fig. 2 -RRB-	28869
the controls and the cABC-treated rats , respectively	28869
the controls and the cABC-treated rats	28869
the controls	28869
the cABC-treated rats	28886
Fig. 2	28923
Partial locomotor recovery	28932
combined treatment	28968
the spinal cord transection	29004
all animals	29033
complete , flaccid paralysis of the hindlimbs	29055
complete , flaccid paralysis	29055
the hindlimbs	29086
Slight recovery	29101
spontaneous movements of up to two joints of the hindlegs	29133
spontaneous movements	29133
up to two joints of the hindlegs	29158
up to two joints	29158
the hindlegs	29178
the next 5 weeks	29207
injury -LRB- Fig. 3C -RRB-	29230
injury	29230
Fig. 3C	29238
Rhythmic limb movements	29248
6 weeks	29297
the extensive laminectomy	29333
many animals	29360
severe lordosis	29387
a hunched posture rostral to the laminectomy site	29418
a hunched posture rostral	29418
the laminectomy site	29447
Some rats	29469
signs of spasticity	29494
signs	29494
spasticity	29503
asymmetric muscle tone resulting in asymmetric body posture	29525
asymmetric muscle tone	29525
asymmetric body posture	29561
spasticity	29591
a subjective ranking score	29623
0 , no sign of spasticity ,	29664
0	29664
no sign of spasticity	29667
no sign	29667
spasticity	29678
3 , extensive spasticity	29693
3	29693
extensive spasticity	29696
no difference	29719
groups -LRB- data not shown -RRB-	29751
groups	29751
data not shown	29759
data	29759
Both lordosis and spasticity	29776
locomotor ability	29814
the animal 's functional recovery	29857
the animal 's	29857
the ablation of descending axons	29907
the ablation	29907
descending axons	29923
One unexpected finding	29941
some	29973
rats	29986
movements of the hindlegs	30026
movements	30026
the hindlegs	30039
phases when the animals were standing	30059
phases	30059
the animals	30071
the forelimbs	30101
This	30129
spontaneous activity	30158
the pattern generating networks in the lumbar spinal cord	30182
the pattern	30182
networks in the lumbar spinal cord	30205
networks	30205
the lumbar spinal cord	30217
These sequences	30241
the evaluation of open-field locomotion	30276
the evaluation	30276
open-field locomotion	30294
the BBB rating scale	30322
none	30347
the animals	30355
the spinal cords	30372
the channels	30403
one animal -LRB- grafts only -RRB-	30424
one animal	30424
grafts	30436
the rostral injection of OEG	30450
the rostral injection	30450
OEG	30475
strong inflammation and tissue destruction	30491
a second lesion rostral	30544
the transection spanning ≈ 80 % of the spinal cord	30571
the transection	30571
80 %	30597
the spinal cord	30604
this	30629
the exclusion criteria	30644
this animal	30668
the study	30697
Open-field locomotor score Behavioral testing	30708
Open-field locomotor score	30708
Behavioral testing	30735
9 weeks postlesion -LRB- Fig. 3A -RRB-	30774
9 weeks postlesion	30774
9 weeks	30774
postlesion	30782
Fig. 3A	30794
The average score in the control group -LRB- n = 8 -RRB-	30804
The average score in the control group	30804
The average score	30804
the control group	30825
n	30844
8	30846
2.1 ± 0.7 -LRB- SEM -RRB-	30853
2.1 ± 0.7	30853
2.1	30853
0.7	30857
SEM	30862
the group	30871
transplants	30886
4 ± 0.6 -LRB- n = 6 -RRB-	30902
4 ± 0.6	30902
n	30909
6	30911
the cABC group	30922
6.6 ± 0.7	30941
6.6	30941
0.7	30945
n	30950
5	30952
The average BBB score of the cABC group	30956
The average BBB score	30956
the cABC group	30981
that of the other groups -LRB- p < 0.01 -RRB-	31026
that	31026
the other groups -LRB- p < 0.01 -RRB-	31034
the other groups	31034
p < 0.01	31053
p	31053
< 0.01	31054
<	31054
0.01	31055
The group with the transplants	31062
The group	31062
the transplants	31077
any significant improvements	31109
the BBB score	31141
the control group	31174
No significant difference between the cABC and control groups	31193
No significant difference	31193
the cABC and control groups	31227
8 weeks	31270
injury -LRB- Fig. 3C -RRB-	31284
injury	31284
Fig. 3C	31292
the 7 weeks after injury	31309
the 7 weeks	31309
injury	31327
the BBB scores	31335
0 and 4 points	31365
The first signs of recovery in locomotor functions	31381
The first signs	31381
recovery in locomotor functions	31400
recovery	31400
locomotor functions	31412
the cABC group and the rats	31489
the cABC group	31489
the rats	31508
Matrigel only , at 8 weeks	31522
Matrigel only	31522
8 weeks	31540
The results	31549
the recovery	31575
not plateau	31592
9 weeks	31607
the injury , the time point at which testing was discontinued	31621
the injury	31621
the time point at which testing was discontinued	31633
the time point	31633
testing	31657
A representative walking sequence	31683
a rat from the cABC group with forelimb and hindlimb activity	31720
a rat	31720
the cABC group with forelimb and hindlimb activity	31731
the cABC group	31731
forelimb and hindlimb activity	31751
Figure 4	31794
Forelimb/hindlimb coupling This analysis	31804
Forelimb/hindlimb coupling	31804
This analysis	31831
information	31866
the tendency of forelimb and hindlimb movements	31881
the tendency	31881
forelimb and hindlimb movements	31897
alternate	31932
hindlimb coupling	31953
the BBB score	31988
animals	32010
that	32018
weight-supported plantar stepping	32043
weight-supported plantar	32043
animals with lower locomotor capabilities	32090
animals	32090
lower locomotor capabilities	32103
this	32133
an important outcome measure	32146
A measure of the frequency of movements and a relation to forelimb stepping	32176
A measure	32176
the frequency of movements and a relation to forelimb stepping	32189
the frequency of movements	32189
the frequency	32189
movements	32206
a relation to forelimb stepping	32220
a relation	32220
forelimb stepping	32234
forelimb	32234
complete SCI	32279
the percentage of hindlimb steps after forelimb steps	32304
the percentage	32304
hindlimb steps after forelimb steps	32322
hindlimb steps	32322
forelimb steps	32343
assessment	32376
one video recording for each animal at 9 weeks after injury	32388
one video recording	32388
each animal at 9 weeks after injury	32412
each animal	32412
9 weeks after injury	32427
9 weeks	32427
injury	32441
The results	32458
Figure 3B	32488
the open-field locomotor score	32505
the untreated rats	32537
the lowest percentage of forelimb/hindlimb coupling	32563
the lowest percentage	32563
forelimb/hindlimb coupling	32588
18.5 ± 0.5 %	32620
18.5 ±	32620
This	32633
the group	32671
grafts only -LRB- 38.3 ± 0.7 % -RRB-	32686
grafts	32686
only -LRB- 38.3 ± 0.7 % -RRB-	32693
only	32693
38.3 ± 0.7 %	32699
38.3	32699
0.7 %	32706
The best coupling	32713
the group	32746
grafts and cABC -LRB- 70 ± 3.4 % -RRB-	32761
grafts	32761
cABC -LRB- 70 ± 3.4 % -RRB-	32772
cABC	32772
70 ± 3.4 %	32778
70	32778
3.4 %	32783
This improvement	32790
the untreated and the grafted groups	32849
Role of sensory feedback in hindlimb movement	32887
Role	32887
sensory feedback in hindlimb movement	32895
sensory feedback	32895
hindlimb movement	32915
hindlimb movements	32952
sensory feedback	32988
the sliding of hindlegs	33020
the sliding	33020
hindlegs	33035
forelimb stepping	33051
forelimb	33051
commands	33093
motor tracts	33121
we	33135
locomotion	33147
three different surfaces	33161
The first	33187
a smooth Plexiglas surface used for all open-field testing	33201
a smooth Plexiglas surface	33201
all open-field testing	33237
the second	33261
a Plexiglas surface	33276
a thin layer of oil -LRB- referred to as a slippery surface -RRB-	33309
a thin layer	33309
oil	33325
a slippery surface	33345
the third	33370
a carpet -LRB- rough surface -RRB-	33384
a carpet	33384
rough surface	33394
None of the groups on the rough surface	33410
None	33410
the groups on the rough surface	33418
the groups	33418
the rough surface	33432
the prediction	33470
cutaneous feedback	33500
the hindlimbs	33522
the surface would enhance the hindlimb activity	33554
the surface	33554
the hindlimb activity	33580
the carpet	33611
friction	33632
the forelimbs	33642
propulsion	33678
this	33694
a nonquantified , but obvious , increase in walking speed	33711
a nonquantified , but obvious , increase	33711
speed	33761
The forelimb/hindlimb	33768
score was either reduced -LRB- p < 0.05 in four animals -RRB-	33799
score was either reduced	33799
score	33799
p < 0.05 in four animals	33826
p	33826
< 0.05 in four animals	33828
<	33828
0.05 in four animals	33830
0.05	33830
four animals	33838
Walking	33880
the fore limbs	33891
the slippery runway	33909
necessary , a slight tilt of the surface	33937
necessary , a slight tilt	33937
necessary	33937
a slight tilt	33948
the surface	33965
stationary walking	33990
The rats	34010
a rhythmic stepping pattern	34028
the forelimbs	34061
the rest of the body relative to the surface	34090
the rest	34090
the body relative to the surface	34102
the body	34102
the surface	34123
sensory feedback	34160
the hindlimbs	34180
these conditions	34201
it	34219
the rats	34243
only very few stepping sequences	34265
only very few	34265
sequences	34288
We	34313
sequences	34327
locomotion	34355
hindlimb activation	34378
this	34407
the idea	34426
forelimbs and hindlimbs	34440
direct descending control	34480
locomotion	34532
Alternating activity of both forelimbs and hindlimbs during stationary walking	34544
Alternating activity	34544
both forelimbs and hindlimbs during stationary walking	34568
both forelimbs and hindlimbs	34568
stationary walking	34604
only two of five rats in the cABC group	34636
only two	34636
five rats in the cABC group	34648
five rats	34648
the cABC group	34661
no animals in the remaining groups	34683
no animals	34683
the remaining groups	34697
This result	34719
the idea	34740
animals with alternating forelimb/hindlimb activity	34757
animals	34757
forelimb/hindlimb activity	34782
a reconnection of the caudal with the rostral spinal cord	34810
a reconnection	34810
the caudal with the rostral spinal cord	34828
the caudal	34828
the rostral spinal cord	34844
Cell grafts	34882
response	34904
tactile stimuli	34916
Spinal cord injury	34932
increased responses	34975
mechanical stimuli	34998
cutaneous receptors -LRB- allodynia -RRB-	35020
cutaneous receptors	35020
allodynia	35041
the lesion -LRB- Siddall et al. , 1995 ; Hutchinson et al. , 2004 -RRB-	35058
the lesion	35058
Siddall	35070
et al. , 1995 ; Hutchinson et al. , 2004	35078
et al.	35078
1995 ; Hutchinson et al.	35086
1995	35086
Hutchinson et al.	35092
Hutchinson	35092
et al.	35103
2004	35111
the experimental treatments	35134
these responses	35173
we	35190
the reaction	35200
mechanical stimulation	35216
calibrated von Frey hairs at five different locations below the lesion	35244
calibrated von Frey hairs at five different locations	35244
von Frey hairs at five	35255
von Frey hairs	35255
five	35273
the lesion	35304
A general finding	35316
all rats	35346
the base of the tail	35356
the base	35356
the tail	35368
the most sensitive and most reliably excitable location	35381
the relation of excitability at the different locations	35446
the relation	35446
excitability at the different locations	35462
excitability	35462
the different locations	35478
animals	35525
only data gathered from stimulation at the base of the tail	35534
only data	35534
stimulation	35558
the base of the tail	35573
the base	35573
the tail	35585
The lowest sensitivity -LRB- highest target force to trigger a response -RRB-	35609
The lowest sensitivity	35609
highest target force to trigger a response	35633
highest target force	35633
a response	35665
untreated rats -LRB- Fig. 5 -RRB-	35690
untreated rats	35690
Fig. 5	35706
the average target force at the tip of the von Frey hairs	35715
the average target force	35715
the tip of the von Frey hairs	35743
the tip	35743
the von Frey hairs	35754
0.1 g	35784
This	35791
rats with grafts only -LRB- 0.31 ± 0.07 g -RRB- and with grafts and cABC	35829
rats	35829
grafts only -LRB- 0.31 ± 0.07 g -RRB-	35839
grafts only	35839
grafts	35839
0.31 ± 0.07 g	35852
0.31 ± 0.07	35852
0.31	35852
0.07	35859
g	35864
grafts and cABC	35876
0.33 ± 0.08 g	35893
0.33 ± 0.08	35893
0.33	35893
0.08	35900
g	35905
Grafts and cABC	35909
serotonergic fiber regeneration	35933
this study	35968
we	35980
descending axons from three groups of neurons	35994
descending axons	35994
three groups of neurons	36016
three groups	36016
neurons	36032
the hindlimb area of the motor cortex	36041
the hindlimb area	36041
the motor cortex	36062
the medial reticular formation	36080
the raphe nuclei , which project serotonergic -LRB- 5-HT-positive -RRB- fibers	36116
the raphe nuclei	36116
serotonergic -LRB- 5-HT-positive -RRB- fibers	36148
Serotonergic fibers	36185
the graft and caudal to it	36226
the graft and caudal	36226
it	36250
the abundance	36279
highly branched serotonergic fibers	36296
the caudal spinal cord -LRB- Fig. 6A -RRB-	36335
the caudal spinal cord	36335
Fig. 6A	36359
The quantitative analysis of these fibers	36369
The quantitative analysis	36369
these fibers	36398
the bridge revealed a high variability within the groups	36421
the bridge	36421
a high variability	36441
the groups	36467
the large SD	36490
the increase caused by grafting	36504
the increase	36504
70.1 ± 12.2 , SEM in the rats with grafts only	36557
70.1 ± 12.2 , SEM in the rats	36557
70.1 ± 12.2	36557
70.1	36557
12.2	36564
SEM in the rats	36570
SEM	36570
the rats	36577
grafts only	36591
This increase	36605
the application of cABC -LRB- 94 ± 14.5 -RRB-	36643
the application	36643
cABC -LRB- 94 ± 14.5 -RRB-	36662
cABC	36662
94 ± 14.5	36668
94 ±	36668
14.5	36673
the untreated animals -LRB- 15.5 ± 2.2 -RRB- -LRB- Fig. 6B -RRB-	36732
the untreated animals -LRB- 15.5 ± 2.2 -RRB-	36732
the untreated animals	36732
15.5 ± 2.2	36755
15.5 ±	36755
2.2	36762
Fig. 6B	36768
serotonin in the lumbar spinal cord of injured rats	36787
serotonin	36787
the lumbar spinal cord of injured rats	36800
the lumbar spinal cord	36800
injured rats	36826
powerful effects on locomotor function -LRB- Ribotta et al. , 1998 , 2000 -RRB-	36843
powerful effects	36843
locomotor function -LRB- Ribotta et al. , 1998 , 2000 -RRB-	36863
locomotor function	36863
Ribotta	36883
et al. , 1998 , 2000	36891
et al.	36891
1998	36899
2000	36905
no correlation between the number of serotonergic fibers	36912
no correlation	36912
the number of serotonergic fibers	36935
the number	36935
serotonergic fibers	36949
caudal to the bridge and locomotor recovery	36975
caudal	36975
the bridge and locomotor recovery	36985
our experiment -LRB- Fig. 6C -RRB-	37032
our experiment	37032
Fig. 6C	37048
Detectable	37058
axons of two descending motor tracts -LRB- CST and RtST -RRB-	37080
axons	37080
two descending motor tracts -LRB- CST and RtST -RRB-	37089
two descending motor tracts	37089
CST and RtST	37118
CST	37118
RtST	37126
rostral	37146
the lesion	37157
Only a few of these traced axons	37169
Only a few	37169
these traced axons	37183
the bridge	37221
none	37237
the caudal part of the spinal cord -LRB- data not shown -RRB-	37265
the caudal part	37265
the spinal cord -LRB- data not shown -RRB-	37284
the spinal cord	37284
data not shown	37301
data	37301
axons	37329
blood	37339
the bridge Quantification of myelinated axons	37356
the bridge Quantification	37356
myelinated axons	37385
transverse	37437
1 µm sections obtained from the center of the bridge	37448
1 µm sections	37448
the center of the bridge	37476
the center	37476
the bridge	37490
These counts	37502
both	37530
fibers that can not be distinguished by this approach -LRB- Fig. 7 -RRB-	37560
fibers	37560
this approach -LRB- Fig. 7 -RRB-	37599
this approach	37599
Fig. 7	37614
The lowest count	37623
the control group with an average of 1009 ±	37653
the control group	37653
an average of 1009 ±	37676
an average	37676
1009 ±	37690
237 -LRB- SEM -RRB- myelinated axons	37697
237 -LRB- SEM -RRB-	37697
myelinated axons	37707
the group with grafts , the average number was -LRB- 1949 ± 486 -RRB-	37728
the group	37728
grafts , the average number was	37743
grafts	37743
the average number was	37751
the average number	37751
1949 ± 486	37775
1949 ±	37775
486	37780
which	37786
The cABC group	37825
significantly higher numbers of myelinated axons	37850
significantly higher numbers	37850
myelinated axons	37882
the control group -LRB- 3058 ± 600 -RRB- -LRB- Fig. 8A -RRB-	37918
the control group -LRB- 3058 ± 600 -RRB-	37918
the control group	37918
3058 ± 600	37937
3058 ±	37937
600	37944
Fig. 8A	37950
the individual axon counts	37965
the functional outcomes	38011
open-field locomotion and forelimb/hindlimb coupling	38036
a significant correlation -LRB- r = 0.63 -RRB-	38091
a significant correlation	38091
r	38118
0.63	38122
Fig. 8C	38139
axonal regeneration through the bridge	38165
axonal regeneration	38165
the bridge	38193
the observed functional recovery	38219
The number of blood vessels in the bridge	38253
The number	38253
blood vessels in the bridge	38267
blood vessels	38267
the bridge	38284
either of the groups -LRB- Fig. 8B -RRB-	38342
either	38342
the groups -LRB- Fig. 8B -RRB-	38352
the groups	38352
Fig. 8B	38364
vascularization	38386
the graft	38405
the viability of the grafted cells within the bridge	38443
the viability	38443
the grafted cells within the bridge	38460
the grafted cells	38460
the bridge	38485
support of axonal regeneration	38511
support	38511
axonal regeneration	38522
The average numbers	38543
blood vessels in the graft for the groups with no treatment	38566
blood vessels	38566
the graft for the groups with no treatment	38583
the graft	38583
the groups with no treatment	38597
the groups	38597
no treatment	38613
grafts/cABC	38644
264 ± 43 -LRB- SEM -RRB- , 357 ± 43 , and 414 ± 50	38661
264 ± 43 -LRB- SEM -RRB-	38661
264 ± 43	38661
264	38661
43	38667
SEM	38671
357 ± 43	38677
357	38677
43	38683
414 ± 50	38691
414	38691
50	38697
Discussion Testing the interaction of established experimental treatments	38716
Discussion	38716
the interaction of established experimental treatments	38735
the interaction	38735
established experimental treatments	38754
an important step in developing additive , more efficacious treatments for SCI	38793
an important step	38793
additive , more efficacious treatments for SCI	38825
additive , more efficacious treatments	38825
SCI	38867
Our study addresses this need and	38872
study addresses	38876
this need	38892
direction for the refinement of future treatments	38915
direction	38915
the refinement of future treatments	38929
the refinement	38929
future treatments	38947
untreated rats	38985
only the group of animals subjected to cell grafts and cABC treatment	39001
only the group	39001
animals subjected to cell grafts and cABC treatment	39019
animals	39019
cell grafts and cABC treatment	39040
cell grafts	39040
cABC treatment	39056
statistically significant improvements	39078
locomotor recovery	39120
both the BBB score and forelimb/hindlimb coupling measurements	39153
Recovery	39217
the endpoint of the study	39245
the endpoint	39245
the study	39261
8 weeks	39275
the injury	39289
a time	39301
axonal regeneration	39358
the graft	39386
the caudal stump -LRB- Xu et al. , 1995b , 1997 ; Steward et al. , 2003 -RRB-	39405
the caudal stump	39405
Xu et al. , 1995b , 1997 ; Steward et al. , 2003	39423
Xu	39423
et al. , 1995b , 1997 ; Steward et al. , 2003	39426
et al.	39426
1995b	39434
1997 ; Steward et al.	39441
1997	39441
Steward et al.	39447
Steward	39447
et al.	39455
2003	39463
It	39470
the functional benefits of the current treatments	39493
the functional benefits	39493
the current treatments	39520
at least two reasons	39584
the time course	39613
recovery	39646
plateau	39663
the end of the allotted testing period	39674
the end	39674
the allotted testing period	39685
A longer experimental time course	39714
the long-term benefits of the combinatory treatment	39790
the long-term benefits	39790
the combinatory treatment	39816
small animal numbers in the groups	39872
small animal numbers	39872
the groups	39896
the possible loss of animals before fiber tracing	39912
the possible loss	39912
animals before fiber tracing	39933
animals	39933
fiber tracing	39948
fiber	39948
the laminectomy of three vertebral segments without artificial stabilization	39990
the laminectomy	39990
three vertebral segments without artificial stabilization	40009
three vertebral segments	40009
artificial stabilization	40042
strong lordosis , further hampering locomotor recovery	40079
strong lordosis	40079
further hampering locomotor recovery	40096
further	40096
locomotor recovery	40114
The hunched body posture	40134
the nervous system	40226
sufficient motor control	40259
the results	40299
the grafts consisting of SCs and OEG and the application of cABC	40336
the grafts	40336
SCs and OEG and the application of cABC	40361
SCs and OEG	40361
SCs	40361
OEG	40369
the application of cABC	40377
the application	40377
cABC	40396
additive effects	40406
Our results	40424
the beneficial effects of cABC	40465
the beneficial effects	40465
cABC	40491
axonal regeneration	40499
complete spinal cord	40525
support previous reports	40562
cABC application	40596
salutary effects	40628
brain injury	40651
Moon	40665
et al. , 2001	40670
et al.	40670
2001	40678
incomplete lesions	40688
the spinal cord -LRB- Bradbury et al. , 2002 ; Yick et al. , 2003 -RRB-	40710
the spinal cord	40710
Bradbury	40727
et al. , 2002 ; Yick et al. , 2003	40736
et al.	40736
2002 ; Yick et al.	40744
2002	40744
Yick et al.	40750
Yick	40750
et al.	40755
2003	40763
The application of cABC	40770
The application	40770
cABC	40789
conjunction	40836
grafted tissue	40853
scar tissue at the graft-host interface	40877
scar tissue	40877
the graft-host interface	40892
a barrier for axons	40928
a barrier	40928
axons	40942
the graft -LRB- Chau et al. , 2004 -RRB-	40973
the graft	40973
Chau	40984
et al. , 2004	40989
et al.	40989
2004	40997
It	41004
one control animal	41026
a BBB score of 6	41053
a BBB score	41053
6	41068
its recovery	41074
the treated group	41113
This recovery	41132
the surgery	41170
any chance of axonal sparing	41193
any chance	41193
axonal sparing	41207
Even a relesion	41223
9 weeks	41239
hindlimb activity	41270
This phenomenon	41289
the plastic capabilities of the spinal networks controlling locomotion	41317
the plastic capabilities	41317
the spinal networks controlling locomotion	41345
the spinal networks	41345
locomotion	41377
review	41393
Pearson , 2000 ; Edgerton et al. , 2001 ; Rossignol et al. , 2002	41405
Pearson , 2000 ; Edgerton et al. , 2001 ; Rossignol et al.	41405
Pearson , 2000	41405
Pearson	41405
2000	41414
Edgerton et al. , 2001	41420
Edgerton	41420
et al. , 2001	41429
et al.	41429
2001	41437
Rossignol et al.	41443
Rossignol	41443
et al.	41453
2002	41461
Another unexpected result	41468
the considerable number of myelinated axons	41498
the considerable number	41498
myelinated axons	41525
serotonergic axons observed in Matrigelonly grafts	41546
serotonergic axons	41546
Matrigelonly grafts	41577
these fibers	41598
Matrigel-only bridges in previous studies -LRB- Xu et al. , 1997 -RRB-	41629
Matrigel-only bridges	41629
previous studies -LRB- Xu et al. , 1997 -RRB-	41654
previous studies	41654
Xu	41672
et al. , 1997	41675
et al.	41675
1997	41683
This	41690
the finding	41699
none of the animals	41719
none	41719
the animals	41727
the spinal cord pulled out of the channel	41743
the spinal cord	41743
the channel	41773
the new technique for implanting an SC bridge used in this study	41808
the new technique	41808
an SC bridge used in this study	41841
an SC bridge	41841
this study	41862
the channel	41884
the SCs	41915
fluid Matrigel	41926
windows on the dorsal surface of the channel	41949
windows	41949
the dorsal surface of the channel	41960
the dorsal surface	41960
the channel	41982
better apposition	42006
the SCs and the spinal cord stumps	42032
the SCs	42032
the spinal cord stumps	42044
It	42068
HRP-labeled CST axons	42094
a graft of collagen	42122
a graft	42122
collagen	42133
the collagen	42147
fluid form	42177
the matrix	42237
the collagen	42253
solid gel form -LRB- Joosten et al. , 1995 -RRB-	42282
solid gel form	42282
Joosten	42298
et al. , 1995	42306
et al.	42306
1995	42314
This study	42321
the	42357
fluid form	42375
it	42387
the surface of the cord stump	42412
the surface	42412
the cord stump	42427
A major question after experimental treatments to repair the injured spinal cord	42443
A major question	42443
experimental treatments	42466
the injured spinal cord	42500
functional recovery	42544
regenerated fibers	42577
appropriate targets	42612
the lesion or changes	42638
the lesion	42638
changes	42652
existing circuitries	42663
the lesion	42700
review	42716
Fouad and Pearson , 2004	42728
Fouad and Pearson	42728
2004	42747
some studies	42762
axonal regeneration and functional recovery	42789
regeneration	42796
complete SCI	42839
treatment -LRB- Cheng et al. , 1996 ; Ramo ' n-Cueto et al. , 2000 -RRB-	42863
treatment	42863
Cheng	42874
et al. , 1996 ; Ramo ' n-Cueto et al. , 2000	42880
et al.	42880
1996 ; Ramo ' n-Cueto et al.	42888
1996	42888
Ramo ' n-Cueto et al.	42894
Ramo ' n-Cueto	42894
Ramo '	42894
et al.	42908
2000	42916
very few	42923
evidence of reconnection	42946
evidence	42946
reconnection	42958
One link between regeneration and functional recovery	42972
One link	42972
regeneration and functional recovery	42989
histological evidence	43029
fibers growing through the graft and into the caudal stump of the spinal cord	43054
fibers	43054
the graft	43077
the caudal stump of the spinal cord	43096
the caudal stump	43096
the spinal cord	43116
fibers of the CST and the RtST	43140
fibers	43140
the CST and the RtST	43150
the CST	43150
the RtST	43162
the SC bridge	43191
none	43210
the bridge	43253
the contiguous caudal cord	43269
contrast	43300
rats with grafted cells in our study	43313
rats	43313
grafted cells in our study	43323
grafted cells	43323
our study	43340
5-HT fibers that grew through the bridge and projected into the caudal stump	43351
5-HT fibers	43351
the bridge	43381
the caudal stump	43411
abundance	43442
This	43453
previous experiments	43467
SC bridges combined with OEG grafts	43497
SC bridges	43497
OEG grafts	43522
the presence of 5-HT fibers	43540
the presence	43540
5-HT fibers	43556
the bridge	43578
a complete transection gap -LRB- Ramo ' n-Cueto et al. , 1998 -RRB-	43599
a complete transection gap	43599
Ramo ' n-Cueto et al. , 1998	43627
Ramo ' n-Cueto et al.	43627
Ramo ' n-Cueto	43627
Ramo '	43627
1998	43649
the application of serotonin	43664
the application	43664
serotonin	43683
the grafting of serotonin-secreting cells to the caudal spinal cord	43696
the grafting	43696
serotonin-secreting cells to the caudal spinal cord	43712
serotonin-secreting cells	43712
the caudal spinal cord	43741
significant locomotor recovery	43788
Ribotta	43820
et al. , 2000 ; Antri et al. , 2002	43828
et al.	43828
2000 ; Antri et al.	43836
2000	43836
Antri et al.	43842
Antri	43842
et al.	43848
2002	43856
it	43863
no correlation	43894
an increased number of serotonergic fibers and locomotor recovery	43917
an increased number	43917
serotonergic fibers and locomotor recovery	43940
serotonergic fibers	43940
locomotor recovery	43964
Possible explanations	43994
greater numbers of regenerating serotonergic fibers	44035
greater numbers	44035
serotonergic fibers	44067
locomotor recovery	44112
they	44132
the lumbar cord	44166
the fibers	44186
The significant correlation	44218
we	44251
functional recovery and the number of myelinated axons	44268
functional recovery	44268
the number of myelinated axons	44292
the number	44292
myelinated axons	44306
the center of the bridge	44326
the center	44326
the bridge	44340
fibers other than CST , RtST , or serotonergic axons	44365
fibers	44365
CST , RtST , or serotonergic axons	44383
CST	44383
RtST	44388
serotonergic axons	44397
the observed recovery	44433
Plausible candidates	44456
axons	44481
propriospinal interneurons	44490
SC bridges	44548
Xu	44560
et al. , 1995b , 1997	44563
et al.	44563
1995b	44571
1997	44578
the interneurons	44585
relays for lesioned axons	44617
relays	44617
lesioned axons	44628
rostral	44653
a lesion	44664
Fouad	44674
et al. , 2001	44680
et al.	44680
2001	44688
Raineteau and Schwab , 2001	44694
Raineteau and Schwab	44694
2001	44716
Raineteau et al. , 2001	44722
Raineteau	44722
et al. , 2001	44732
et al.	44732
2001	44740
Bareyre et al. , 2004	44746
Bareyre	44746
et al. , 2004	44754
et al.	44754
2004	44762
Propriospinal interneurons	44769
the present study	44815
retrograde tracers	44863
future work	44885
the relationship between regeneration and functional recovery	44933
the relationship	44933
regeneration and functional recovery	44958
a relesion of the spinal cord	44996
a relesion	44996
the spinal cord	45010
one rat	45049
it	45066
the anterograde tracing used in our study	45096
the anterograde	45096
our study	45128
A finding supporting a reestablished connection via the lesion site	45139
A finding	45139
a reestablished connection via the lesion site	45160
a	45160
connection via the lesion site	45176
connection	45176
the lesion site	45191
behavioral testing on a slippery surface	45218
behavioral testing	45218
a slippery surface	45240
`` stationary '' forelimb stepping	45267
`` stationary '' forelimb	45267
sensory feedback to the hindlimbs	45299
sensory feedback	45299
the hindlimbs	45319
a minimum	45348
no sliding over the surface	45367
no sliding	45367
the surface	45383
these circumstances	45411
the hindlimbs of a few rats with high locomotor scores	45432
the hindlimbs	45432
a few rats with high locomotor scores	45449
a few rats	45449
high locomotor scores	45465
the forelimbs	45523
both	45554
hindlimb stepping	45572
hindlimb	45572
descending input	45607
Promoting axonal regeneration in the injured spinal cord	45625
Promoting axonal regeneration	45625
the injured spinal cord	45658
descending motor axons	45704
Sprouting and growth of sensory fibers	45728
Sprouting and growth	45728
sensory fibers	45752
our study	45799
sensory fibers	45838
we	45854
responses to tactile cutaneous stimuli in dermatomes	45866
responses	45866
tactile cutaneous stimuli in dermatomes	45879
tactile cutaneous stimuli	45879
dermatomes	45908
the lesion	45929
The finding that treated rats	45941
The finding	45941
rats	45966
significantly increased sensitivity	45981
tactile stimuli	46020
the clinical value of regeneration	46044
the clinical value	46044
regeneration	46066
treatments	46090
increased pain	46110
a treatment	46131
our results	46174
increased pain or allodynia	46231
rats	46270
signs	46282
spasticity in human patients	46304
spasticity	46304
human patients	46318
the increased responses to tactile stimuli	46343
the increased responses	46343
tactile stimuli	46370
a sign	46402
increased spasticity	46412
disinhibition of spinal pathways -LRB- Calancie et al. , 1993 -RRB-	46446
disinhibition	46446
spinal pathways -LRB- Calancie et al. , 1993 -RRB-	46463
spinal pathways	46463
Calancie	46480
et al. , 1993	46489
et al.	46489
1993	46497
changes	46506
neuronal properties -LRB- Bennett et al. , 2004 ; Li et al. , 2004 -RRB-	46517
neuronal properties	46517
Bennett	46538
et al. , 2004 ; Li et al. , 2004	46546
et al.	46546
2004 ; Li et al.	46554
2004	46554
Li et al.	46560
Li	46560
et al.	46563
2004	46571
Increased sensory feedback	46578
locomotor recovery	46638
SCI -LRB- Pearson , 2001 -RRB-	46663
SCI	46663
Pearson	46668
2001	46677
Changes in sensitivity as reported above	46684
Changes	46684
sensitivity as reported above	46695
sensitivity	46695
movements	46757
a rough surface	46783
greater levels of cutaneous feedback	46810
greater levels	46810
cutaneous feedback	46828
this	46857
the case	46870
it	46888
changes in ground	46904
changes	46904
ground	46915
a walking sequence initiate reflex-like stepping	46937
a walking sequence initiate reflex-like	46937
The implications of the current study	46987
The implications	46987
the current study	47007
an important	47030
stone	47052
the development of a combined treatment for SCI	47065
the development	47065
a combined treatment for SCI	47084
a combined treatment	47084
SCI	47109
Additional treatment strategies	47114
the neutralization of myelin-associated inhibitors	47159
the neutralization	47159
myelin-associated inhibitors	47181
Nogo A	47222
Nogo 66	47230
MAG	47239
oligodendrocyte	47248
myelin glycoprotein	47264
Merkler et al. , 2001 ; GrandPre et al. , 2002 ; Liu et al. , 2002	47285
Merkler	47285
et al. , 2001 ; GrandPre et al. , 2002 ; Liu et al. , 2002	47293
et al. , 2001	47293
et al.	47293
2001	47301
GrandPre et al. , 2002	47307
GrandPre	47307
et al. , 2002	47316
et al.	47316
2002	47324
Liu et al. , 2002	47330
Liu	47330
et al. , 2002	47334
et al.	47334
2002	47342
the application	47349
growth and survival-promoting neurotrophic factors	47368
Schnell	47420
et al. , 1994	47428
et al.	47428
1994	47436
Mocchetti and Wrathall , 1995	47442
Mocchetti and Wrathall	47442
1995	47466
Xu et al. , 1995a	47472
Xu	47472
et al. , 1995a	47475
et al.	47475
1995a	47483
Kobayashi et al. , 1997	47490
Kobayashi	47490
et al. , 1997	47500
et al.	47500
1997	47508
Ye and Houle , 1997	47514
Ye	47514
Houle , 1997	47521
Houle	47521
1997	47528
Menei et al. , 1998	47534
Menei	47534
et al. , 1998	47540
et al.	47540
1998	47548
Bamber et al. , 2001	47554
Bamber	47554
et al. , 2001	47561
et al.	47561
2001	47569
Blesch and Tuszynski , 2003	47575
Blesch and Tuszynski	47575
2003	47597
the stimulation of the intrinsic capacity of neurons	47608
the stimulation	47608
the intrinsic capacity of neurons	47627
the intrinsic capacity	47627
neurons	47653
Dergham	47670
et al. , 2002	47678
et al.	47678
2002	47686
Neumann et al. , 2002	47692
Neumann	47692
et al. , 2002	47700
et al.	47700
2002	47708
Qiu et al. , 2002	47714
Qiu	47714
et al. , 2002	47718
et al.	47718
2002	47726
Fournier et al. , 2003	47732
Fournier	47732
et al. , 2003	47741
et al.	47741
2003	47749
Lu et al. , 2004	47755
Lu	47755
et al. , 2004	47758
et al.	47758
2004	47766
Nikulina et al. , 2004	47772
Nikulina	47772
et al. , 2004	47781
et al.	47781
2004	47789
Pearse et al. , 2004a	47795
Pearse	47795
et al. , 2004a	47802
et al.	47802
2004a	47810
their compatibility after complete transection of the spinal cord	47853
their compatibility	47853
complete transection of the spinal cord	47879
complete transection	47879
the spinal cord	47903
References	47921
Aebischer	47932
P	47942
Guenard V	47945
Winn SR	47956
Valentini RF	47965
Galletti PM -LRB- 1988 -RRB- Blindended semipermeable guidance channels	47979
Galletti PM	47979
1988	47992
Blindended semipermeable guidance channels	47998
peripheral nerve regeneration in the absence of a distal nerve stump	48049
peripheral nerve regeneration	48049
the absence of a distal nerve stump	48082
the absence	48082
a distal nerve stump	48097
Brain Res 454:179 -- 187 .	48119
Brain Res 454:179	48119
Brain	48119
Res 454:179	48125
187	48138
Antri M	48143
Orsal D	48152
Barthe JY -LRB- 2002 -RRB- Locomotor recovery	48161
Barthe JY	48161
2002	48172
Locomotor recovery	48178
the chronic spinal rat	48200
effects of long-term treatment with a 5-HT2 agonist	48224
effects	48224
long-term treatment with a 5-HT2 agonist	48235
long-term treatment	48235
a 5-HT2 agonist	48260
Eur J Neurosci 16:467 -- 476 .	48277
Eur J Neurosci 16:467	48277
476	48300
Bamber NI	48305
Li H	48316
Lu X	48322
Oudega M	48328
Aebischer P	48338
Xu XM -LRB- 2001 -RRB- Neurotrophins BDNF	48351
Xu XM -LRB- 2001 -RRB- Neurotrophins	48351
2001	48358
BDNF	48378
NT-3	48387
axonal re-entry	48400
the distal host spinal cord	48421
Schwann cell-seeded mini-channels	48457
Eur J Neurosci 13:257 -- 268 .	48492
Eur J Neurosci 13:257	48492
268	48514
Bareyre FM	48519
Kerschensteiner M	48531
Raineteau O	48550
Mettenleiter TC	48563
Weinmann O	48580
Schwab ME -LRB- 2004 -RRB- The injured spinal cord	48592
Schwab ME	48592
2004	48603
The injured spinal cord	48609
a new intraspinal circuit in adult rats	48653
a new intraspinal circuit	48653
adult rats	48682
Nat Neurosci 7:269 -- 277 .	48694
Nat Neurosci 7:269	48694
277	48714
Basso DM	48719
Beattie MS	48729
Bresnahan JC -LRB- 1995 -RRB-	48741
Bresnahan JC	48741
1995	48755
A sensitive and reliable locomotor rating scale for open field testing in rats	48761
A sensitive and reliable locomotor rating scale	48761
open field testing in rats	48813
open field testing	48813
rats	48835
J Neurotrauma 12:1 -- 21 .	48841
J Neurotrauma 12:1	48841
21	48860
Bennett DJ	48864
Sanelli L	48876
Cooke CL	48887
Harvey PJ , Gorassini MA -LRB- 2004 -RRB-	48897
Harvey PJ	48897
Gorassini MA -LRB- 2004 -RRB-	48908
Gorassini MA	48908
2004	48922
Spastic long-lasting reflexes in the awake rat after sacral spinal cord injury	48928
Spastic long-lasting reflexes	48928
the awake rat after sacral spinal cord injury	48961
the awake rat	48961
sacral spinal cord injury	48981
J Neurophysiol 91:2247 -- 2258 .	49008
J Neurophysiol 91:2247	49008
2258	49031
Blesch A , Tuszynski MH -LRB- 2003 -RRB- Cellular GDNF delivery	49037
Blesch A	49037
Tuszynski MH -LRB- 2003 -RRB- Cellular GDNF delivery	49047
Tuszynski MH	49047
2003	49061
Cellular GDNF delivery	49067
growth of motor and dorsal column sensory axons	49099
growth	49099
motor and dorsal column sensory axons	49109
partial and complete spinal cord transections	49153
remyelination	49211
J Comp Neurol 467:403 -- 417 .	49226
J Comp Neurol 467:403	49226
417	49249
Bradbury EJ	49254
Moon LD	49267
Popat RJ	49276
King VR	49286
Bennett GS	49295
Patel PN	49307
Fawcett JW	49317
McMahon SB -LRB- 2002 -RRB- Chondroitinase ABC	49329
McMahon SB	49329
2002	49341
Chondroitinase ABC	49347
functional recovery	49375
spinal cord injury	49401
Nature 416:636 -- 640 .	49421
Nature 416:636	49421
640	49436
Bregman BS , McAtee M , Dai HN , Kuhn PL -LRB- 1997 -RRB- Neurotrophic factors	49441
Bregman BS	49441
McAtee M	49453
Dai HN	49463
Kuhn PL -LRB- 1997 -RRB- Neurotrophic factors	49471
Kuhn PL	49471
1997	49480
Neurotrophic factors	49486
axonal growth	49516
spinal cord injury and transplantation in the adult rat	49536
spinal cord injury and transplantation	49536
the adult rat	49578
Exp Neurol 148:475 -- 494 .	49593
Exp Neurol 148:475	49593
494	49613
Brosamle C	49618
Huber AB	49630
Fiedler M	49640
Skerra A	49651
Schwab ME	49661
2000	49672
Regeneration of lesioned corticospinal tract fibers in the adult rat	49678
Regeneration	49678
lesioned corticospinal tract fibers in the adult rat	49694
lesioned corticospinal tract fibers	49694
the adult rat	49733
a recombinant , humanized IN-1 antibody fragment	49758
J Neurosci 20:8061 -- 8068 .	49807
J Neurosci 20:8061	49807
8068	49827
Bunge MB , Pearse DD -LRB- 2003 -RRB-	49833
Bunge MB	49833
Pearse DD -LRB- 2003 -RRB-	49843
Pearse DD	49843
2003	49854
strategies	49876
repair of the injured spinal cord	49898
repair	49898
the injured spinal cord	49908
J Rehabil Res Dev 40:55 -- 62 .	49933
J Rehabil Res Dev 40:55	49933
62	49958
Calancie B , Broton JG , Klose KJ , Traad M , Difini J , Ayyar DR	49962
Calancie B	49962
Broton JG	49974
Klose KJ	49985
Traad M	49995
Difini J	50004
Ayyar DR	50014
1993	50024
Evidence that alterations in presynaptic inhibition contribute to segmental hypo	50030
Evidence	50030
alterations in presynaptic inhibition	50044
alterations	50044
presynaptic inhibition	50059
segmental hypo	50096
hyperexcitability after spinal cord injury in man	50116
hyperexcitability	50116
spinal cord injury in man	50140
spinal cord injury	50140
man	50162
Electroencephalogr Clin Neurophysiol 89:177 -- 186 .	50167
Electroencephalogr Clin Neurophysiol 89:177	50167
186	50211
Chau CH , Shum DK , Li H , Pei J , Lui YY , Wirthlin L , Chan YS , XuXM	50216
Chau CH	50216
Shum DK	50225
Li H	50234
Pei J	50240
Lui YY	50247
Wirthlin L	50255
Chan YS	50267
XuXM	50276
2004	50282
Chondroitinase ABC	50288
axonal regrowth	50316
Schwann	50340
guidance channels	50359
spinal cord injury	50383
FASEB J 18:194 -- 196 .	50403
FASEB J	50403
18:194 -- 196	50411
Chen A	50424
Xu XM	50432
Kleitman N	50439
Bunge MB -LRB- 1996 -RRB- Methylprednisolone administration	50451
Bunge MB	50451
1996	50461
Methylprednisolone administration	50467
axonal regeneration	50510
Schwann cell grafts in transected adult rat thoracic spinal cord	50535
Schwann cell grafts	50535
transected adult rat thoracic spinal cord	50558
transected adult rat	50558
thoracic spinal cord	50579
Exp Neurol 138:261 -- 276 .	50601
Exp Neurol 138:261	50601
276	50620
Cheng H	50625
Cao Y	50634
Olson L -LRB- 1996 -RRB- Spinal cord repair	50641
Olson L	50641
1996	50650
Spinal cord repair	50656
adult paraplegic rats	50678
partial restoration of hind limb function	50701
partial restoration	50701
hind limb function	50724
Science 273:510 -- 513 .	50744
Science 273:510	50744
513	50761
Coumans JV	50766
Lin TT	50778
Dai HN	50786
MacArthur L	50794
McAtee M	50807
Nash C	50817
Bregman BS -LRB- 2001 -RRB- Axonal regeneration	50825
Bregman BS	50825
2001	50837
Axonal regeneration	50843
functional recovery	50867
complete spinal cord transection	50893
rats by delayed treatment with transplants and neurotrophins	50929
rats	50929
delayed treatment with transplants and neurotrophins	50937
delayed treatment	50937
transplants and neurotrophins	50960
J Neurosci 21:9334 -- 9344 .	50991
J Neurosci 21:9334	50991
9344	51011
Dergham P	51017
Ellezam B	51028
Essagian C	51039
Avedissian H	51051
Lubell WD	51065
McKerracher L -LRB- 2002 -RRB- Rho signaling pathway	51076
McKerracher L	51076
2002	51091
Rho signaling pathway	51097
spinal cord repair	51139
J Neurosci 22:6570 -- 6577 .	51159
J Neurosci 22:6570	51159
6577	51178
Edgerton VR	51184
Leon RD	51197
Harkema SJ	51206
Hodgson JA	51218
London N	51230
Reinkensmeyer DJ	51240
Roy RR	51258
Talmadge RJ	51266
Tillakaratne NJ , Timoszyk W	51279
Tillakaratne NJ	51279
Timoszyk W	51296
Tobin A -LRB- 2001 -RRB-	51308
Tobin A	51308
2001	51317
the injured spinal cord	51334
J Physiol -LRB- Lond -RRB- 533:15 -- 22 .	51359
J Physiol -LRB- Lond -RRB- 533:15	51359
J Physiol	51359
Lond	51370
533:15	51376
22	51383
Fawcett JW , Asher	51387
1999	51409
The glial scar and central nervous system repair	51415
glial scar	51419
Brain Res Bull 49:377 -- 391 .	51465
Brain Res Bull 49:377	51465
391	51487
Fouad K	51492
Pearson K -LRB- 2004 -RRB- Restoring walking after spinal cord injury	51501
Pearson K -LRB- 2004 -RRB-	51501
Pearson K	51501
2004	51512
spinal cord injury	51542
Prog Neurobiol 73:107 -- 126 .	51562
Prog Neurobiol	51562
73:107 -- 126	51577
Fouad K	51589
Pedersen V	51598
Schwab ME	51610
Brosamle C	51621
2001	51633
Cervical sprouting of corticospinal fibers after thoracic spinal cord injury	51639
Cervical	51639
corticospinal fibers	51661
thoracic spinal cord injury	51688
shifts	51728
motor responses	51745
Curr Biol 11:1766 -- 1770 .	51762
Curr Biol 11:1766	51762
1770	51781
Fournier AE	51787
Takizawa BT	51800
Strittmatter SM -LRB- 2003 -RRB- Rho kinase inhibition	51813
Strittmatter SM	51813
2003	51830
Rho kinase inhibition	51836
axonal regeneration in the injured CNS	51867
axonal regeneration	51867
the injured CNS	51890
J Neurosci 23:1416 -- 1423 .	51907
J Neurosci 23:1416	51907
1423	51927
GrandPre T	51933
Li S	51945
Strittmatter SM -LRB- 2002 -RRB- Nogo-66 receptor antagonist peptide	51951
Strittmatter SM	51951
2002	51968
Nogo-66 receptor antagonist peptide	51974
axonal regeneration	52019
Nature 417:547 -- 551 .	52040
Nature 417:547	52040
551	52055
Guth L	52060
Zhang Z	52068
Roberts E -LRB- 1994 -RRB- Key role	52077
Roberts E	52077
1994	52088
Key role	52094
pregnenolone	52107
combination therapy	52123
recovery	52157
spinal cord injury	52172
Proc Natl Acad Sci USA 91:12308 -- 12312 .	52192
Proc Natl Acad Sci USA 91:12308	52192
12312	52225
Herzog A , Brosamle C -LRB- 1997 -RRB- `` Semifree-floating '' treatment	52232
Herzog A	52232
Brosamle C -LRB- 1997 -RRB- `` Semifree-floating '' treatment	52242
Brosamle C	52242
1997	52254
`` Semifree-floating '' treatment	52260
a simple and fast method	52291
process consecutive sections for immunohistochemistry and neuronal tracing	52319
process consecutive sections	52319
immunohistochemistry and neuronal	52352
J Neurosci Methods 72:57 -- 63 .	52395
J Neurosci Methods	52395
72:57 -- 63	52414
Hutchinson KJ	52425
Gomez-Pinilla F	52440
Crowe MJ	52457
Ying Z	52467
Basso DM -LRB- 2004 -RRB- Three exercise paradigms	52475
Basso DM	52475
2004	52485
Three exercise paradigms	52491
sensory recovery	52539
spinal cord contusion in rats	52562
spinal cord contusion	52562
rats	52587
Brain 127:1403 -- 1414 .	52593
Brain 127:1403	52593
1414	52608
Joosten EA	52614
Bar PR	52626
Gispen WH -LRB- 1995 -RRB- Collagen implants	52634
Gispen WH -LRB- 1995 -RRB- Collagen	52634
1995	52645
implants	52660
corticospinal axonal growth	52673
mid-thoracic spinal cord lesion in the adult rat	52707
mid-thoracic spinal cord lesion	52707
the adult rat	52742
J Neurosci Res 41:481 -- 490 .	52757
J Neurosci Res 41:481	52757
490	52780
Kobayashi NR	52785
Fan DP	52799
Giehl KM	52807
Bedard AM	52817
Wiegand SJ	52828
Tetzlaff W -LRB- 1997 -RRB- BDNF and NT-4	52840
Tetzlaff W	52840
1997	52852
BDNF and NT-4	52858
5	52872
atrophy	52882
rat rubrospinal neurons	52893
cervical axotomy	52923
GAP-43 and T 1-tubulin mRNA expression	52951
axonal regeneration	53003
J Neurosci 17:9583 -- 9595 .	53024
J Neurosci 17:9583	53024
9595	53043
Li S	53049
Strittmatter SM -LRB- 2003 -RRB- Delayed systemic Nogo-66 receptor antagonist	53055
Strittmatter SM -LRB- 2003 -RRB-	53055
Strittmatter SM	53055
2003	53072
systemic Nogo-66 receptor antagonist	53086
recovery	53132
spinal cord injury	53146
J Neurosci 23:4219 -- 4227 .	53166
J Neurosci 23:4219	53166
4227	53185
Li Y	53191
Field PM	53197
Raisman G -LRB- 1997 -RRB- Repair of adult rat	53207
Raisman G -LRB- 1997 -RRB- Repair	53207
1997	53218
adult rat	53234
corticospinal tract by transplants of olfactory ensheathing cells	53244
corticospinal tract	53244
transplants of olfactory ensheathing cells	53267
transplants	53267
olfactory ensheathing cells	53282
Science 277:2000 -- 2002 .	53311
Science 277:2000	53311
2002	53329
Li Y	53335
Harvey PJ	53341
Li X	53352
Bennett DJ	53358
2004	53370
Spastic long-lasting reflexes of the chronic spinal rat	53376
Spastic long-lasting reflexes	53376
the chronic spinal rat	53409
J Neurophysiol 91:2236 -- 2246 .	53450
J Neurophysiol 91:2236	53450
2246	53474
Liu BP	53480
Fournier A	53488
GrandPre T , Strittmatter SM -LRB- 2002 -RRB-	53500
GrandPre T	53500
Strittmatter SM -LRB- 2002 -RRB-	53512
Strittmatter SM	53512
2002	53529
Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor	53535
Myelin-associated glycoprotein	53535
a functional ligand for the Nogo-66 receptor	53569
a functional ligand	53569
the Nogo-66 receptor	53593
Science 297:1190 -- 1193 .	53615
Science 297:1190	53615
1193	53633
Lu P	53639
Yang H	53645
Jones LL	53653
Filbin MT	53663
Tuszynski MH	53674
2004	53688
Combinatorial therapy with neurotrophins and cAMP	53694
Combinatorial therapy	53694
neurotrophins and cAMP	53721
axonal regeneration	53753
sites of spinal cord injury	53780
sites	53780
spinal cord injury	53789
J Neurosci 24:6402 -- 6409 .	53809
J Neurosci 24:6402	53809
6409	53829
Meijs MFL	53835
Timmers L	53846
Pearse DD	53857
Tresco PA	53868
Bates ML	53879
Joosten EAJ	53889
Bunge MB	53902
Oudega M -LRB- 2004 -RRB- Basic fibroblast growth factor	53912
Oudega M	53912
2004	53922
Basic fibroblast growth factor	53928
neuronal survival and angiogenesis	53968
neuronal survival	53968
angiogenesis	53990
axonal regeneration and myelination	54011
a Schwann cell bridge in the transected adult rat	54050
a Schwann cell bridge	54050
the transected adult rat	54075
thoracic spinal cord	54100
J Neurotrauma 21:1415 -- 1430 .	54122
J Neurotrauma 21:1415	54122
1430	54144
Menei P	54150
Montero-Menei C	54159
Whittemore SR	54176
Bunge RP	54191
Bunge MB -LRB- 1998 -RRB- Schwann cells	54201
Bunge MB	54201
1998	54211
Schwann cells	54217
human BDNF	54263
enhanced axonal regrowth across transected adult rat spinal cord	54282
enhanced axonal regrowth	54282
transected adult rat spinal cord	54314
Eur J Neurosci 10:607 -- 621 .	54348
Eur J Neurosci 10:607	54348
621	54371
Merkler D	54376
Metz GA	54387
Raineteau O	54396
Dietz V	54409
Schwab ME	54418
Fouad K -LRB- 2001 -RRB- Locomotor recovery	54429
Fouad K -LRB- 2001 -RRB- Locomotor	54429
2001	54438
recovery	54454
spinal cord-injured rats	54466
an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A	54504
an antibody	54504
the myelin-associated neurite growth inhibitor Nogo-A	54529
J Neurosci 21:3665 -- 3673 .	54584
J Neurosci 21:3665	54584
3673	54603
Mocchetti	54609
I , Wrathall JR -LRB- 1995 -RRB-	54619
I	54619
Wrathall JR -LRB- 1995 -RRB-	54622
Wrathall JR	54622
1995	54635
Neurotrophic factors in central nervous system trauma	54641
Neurotrophic factors	54641
central nervous system trauma	54665
J Neurotrauma 12:853 -- 870 .	54696
J Neurotrauma 12:853	54696
870	54718
Moon LD	54723
Asher RA	54732
Rhodes KE	54742
Fawcett JW -LRB- 2001 -RRB-	54753
Fawcett JW	54753
2001	54765
Regeneration of CNS axons	54771
Regeneration	54771
CNS axons	54787
their target following treatment of adult rat brain with chondroitinase ABC	54805
their target following treatment	54805
adult rat brain with chondroitinase ABC	54841
adult rat brain	54841
chondroitinase ABC	54862
Nat Neurosci 4:465 -- 466 .	54882
Nat Neurosci 4:465	54882
466	54902
Moon LD	54907
Asher RA	54916
Rhodes KE	54926
Fawcett JW -LRB- 2002 -RRB- Relationship	54937
Fawcett JW -LRB- 2002 -RRB-	54937
Fawcett JW	54937
2002	54949
axons , proteoglycans and glial cells	54986
axons	54986
proteoglycans	54993
glial cells	55011
unilateral nigrostriatal axotomy in the adult rat	55033
unilateral nigrostriatal axotomy	55033
the adult rat	55069
Neuroscience 109:101 -- 117 .	55084
Neuroscience 109:101	55084
117	55105
Morrissey TK	55110
Kleitman N	55124
Bunge RP -LRB- 1991 -RRB- Isolation	55136
Bunge RP -LRB- 1991 -RRB-	55136
Bunge RP	55136
1991	55146
functional characterization of Schwann cells	55166
functional characterization	55166
Schwann cells	55197
adult peripheral nerve	55224
J Neurosci 11:2433 -- 2442 .	55248
J Neurosci 11:2433	55248
2442	55267
Mu X	55273
Azbill RD	55279
Springer JE -LRB- 2000 -RRB- Riluzole	55290
2000	55303
methylprednisolone combined treatment	55322
functional recovery in traumatic spinal cord injury	55369
functional recovery	55369
traumatic spinal cord injury	55392
J Neurotrauma 17:773 -- 780 .	55422
J Neurotrauma 17:773	55422
780	55443
Neumann S	55448
Bradke F	55459
Tessier-Lavigne M	55469
Basbaum AI	55488
2002	55500
Regeneration of sensory axons within the injured spinal cord	55506
Regeneration	55506
sensory axons within the injured spinal cord	55522
sensory axons	55522
the injured spinal cord	55543
intraganglionic cAMP elevation	55578
Neuron 34:885 -- 893 .	55610
Neuron 34:885	55610
893	55625
Nikulina E	55630
Tidwell JL	55642
Dai HN	55654
Bregman BS	55662
Filbin MT -LRB- 2004 -RRB- The phosphodiesterase inhibitor rolipram	55674
Filbin MT	55674
2004	55685
The phosphodiesterase inhibitor rolipram	55691
a spinal cord lesion	55748
axonal regeneration and functional recovery	55778
axonal regeneration	55778
functional recovery	55802
Proc Natl Acad Sci USA 101:8786 -- 8790 .	55823
Proc Natl Acad Sci USA 101:8786	55823
8790	55855
Novikova LN	55861
Novikov LN	55874
Kellerth JO -LRB- 2002 -RRB-	55886
Kellerth JO	55886
2002	55899
Differential effects	55905
neurotrophins on neuronal survival	55929
neurotrophins	55929
neuronal survival	55946
axonal regeneration after spinal cord injury in adult rats	55968
axonal regeneration	55968
spinal cord injury in adult rats	55994
spinal cord injury	55994
adult rats	56016
J Comp Neurol 452:255 -- 263 .	56028
J Comp Neurol 452:255	56028
263	56050
Novikova LN	56055
Novikov LN	56068
Kellerth JO -LRB- 2003 -RRB- Biopolymers	56080
2003	56093
biodegradable smart implants for tissue regeneration after spinal cord injury	56115
biodegradable smart implants	56115
tissue regeneration after spinal cord injury	56148
tissue regeneration	56148
spinal cord injury	56174
Curr Opin Neurol 16:711 -- 715 .	56194
Curr Opin Neurol 16:711	56194
715	56218
Paxinos G , Watson C -LRB- 1986 -RRB- The rat brain in stereotaxic coordinates .	56223
Paxinos G	56223
Watson C -LRB- 1986 -RRB- The rat brain in stereotaxic coordinates	56234
Watson C	56234
1986	56244
The rat brain in stereotaxic	56250
The rat brain	56250
San Diego : Academic .	56292
San Diego	56292
Academic	56303
Pearse DD -LRB- 2004 -RRB- Targeting	56313
2004	56324
molecules	56364
the neuron to promote repair after spinal cord injury	56381
repair	56403
spinal cord injury	56416
Top Spinal Cord Inj Rehabil 10:1 -- 16 .	56436
Top Spinal Cord Inj Rehabil 10:1	56436
Top Spinal Cord Inj	56436
Rehabil 10:1	56456
16	56469
Pearse DD	56473
Pereira FC	56484
Marcillo AE	56496
Bates ML	56509
Berrocal YA	56519
Filbin MT	56532
Bunge MB -LRB- 2004a -RRB- cAMP	56543
Bunge MB	56543
2004a	56553
cAMP	56560
Schwann cells	56569
axonal growth and functional recovery	56591
spinal cord injury	56635
Nat Med 10:610 -- 616 .	56655
Nat Med 10:610	56655
616	56670
Pearse DD	56675
Marcillo AE	56686
Oudega M	56699
Lynch MP	56709
Wood PM	56719
Bunge MB -LRB- 2004b -RRB- Transplantation of Schwann cells	56728
Bunge MB -LRB- 2004b -RRB- Transplantation	56728
Bunge MB -LRB- 2004b -RRB-	56728
Bunge MB	56728
2004b	56738
Schwann cells	56764
olfactory ensheathing glia after spinal cord injury	56782
olfactory ensheathing glia	56782
spinal cord injury	56815
pretreatment	56839
methylprednisolone and interleukin-10	56857
recovery	56903
J Neurotrauma 21:1223 -- 1239 .	56913
J Neurotrauma 21:1223	56913
1239	56935
Pearson KG -LRB- 2000 -RRB- Plasticity of neuronal networks in the spinal cord	56941
Pearson KG -LRB- 2000 -RRB- Plasticity	56941
Pearson KG -LRB- 2000 -RRB-	56941
Pearson KG	56941
2000	56953
neuronal networks in the spinal cord	56973
neuronal networks	56973
the spinal cord	56994
modifications in response to altered sensory input	57011
modifications	57011
response to altered sensory input	57028
response	57028
altered sensory input	57040
Prog Brain Res 128:61 -- 70 .	57063
Prog Brain Res 128:61	57063
Prog Brain	57063
Res 128:61	57074
70	57085
Pearson KG -LRB- 2001 -RRB-	57089
Pearson KG	57089
2001	57101
reflex function	57122
locomotion	57162
spinal cord repair	57179
J Physiol -LRB- Lond -RRB- 533:75 -- 81 .	57199
J Physiol -LRB- Lond -RRB- 533:75	57199
J Physiol	57199
Lond	57210
533:75	57216
81	57224
Qiu J	57228
Cai D	57235
Dai H	57242
McAtee M	57249
Hoffman PN	57259
Bregman BS	57271
FilbinMT -LRB- 2002 -RRB- Spinal axon regeneration	57283
FilbinMT	57283
2002	57293
Spinal axon regeneration	57299
elevation of cyclic AMP	57335
elevation	57335
cyclic AMP	57348
Neuron 34:895 -- 903 .	57360
Neuron 34:895	57360
903	57374
Raineteau O	57379
Schwab ME -LRB- 2001 -RRB- Plasticity	57392
Schwab ME -LRB- 2001 -RRB-	57392
Schwab ME	57392
2001	57403
motor systems after incomplete spinal cord injury	57423
motor systems	57423
incomplete spinal cord injury	57443
Nat Rev Neurosci 2:263 -- 273 .	57474
Nat Rev Neurosci	57474
2:263 -- 273	57491
Raineteau O , Fouad K , Noth P , Thallmair M , SchwabME	57502
Raineteau O	57502
Fouad K	57515
Noth P	57524
Thallmair M	57532
SchwabME	57545
-LRB- 2001 -RRB- Functional switch	57554
2001	57555
motor tracts in the presence of the mAb IN-1 in the adult rat	57587
motor tracts	57587
the presence of the mAb IN-1 in the adult rat	57603
the presence	57603
the mAb IN-1 in the adult rat	57619
the mAb IN-1	57619
the adult rat	57635
Proc Natl Acad Sci USA 98:6929 -- 6934 .	57650
Proc Natl Acad Sci USA 98:6929	57650
6934	57681
Ramo ' n-Cueto A	57687
Ramo '	57687
Plant GW	57704
Avila J	57714
BungeMB -LRB- 1998 -RRB- Long distance axonal regeneration	57723
BungeMB	57723
1998	57732
Long distance axonal regeneration	57738
the transected adult rat spinal cord	57775
glia transplants	57839
J Neurosci 18:3803 -- 3815 .	57857
J Neurosci 18:3803	57857
3815	57876
Ramo ' n-Cueto A , Cordero MI , Santos-Benito FF ,	57882
Ramo ' n-Cueto A	57882
Ramo '	57882
Cordero MI , Santos-Benito FF ,	57899
Cordero MI	57899
Santos-Benito FF	57911
Avila J	57929
-LRB- 2000 -RRB- Functional recovery of paraplegic rats	57937
-LRB- 2000 -RRB- Functional recovery	57937
2000	57938
paraplegic rats	57967
motor axon regeneration in their spinal cords	57987
motor axon regeneration	57987
their spinal cords	58014
olfactory ensheathing glia	58036
Neuron 25:425 -- 435 .	58064
Neuron 25:425	58064
435	58079
Ribotta MG	58084
Orsal D	58096
Feraboli-Lohnherr D	58105
Privat A	58126
Provencher J	58136
Rossignol S -LRB- 1998 -RRB-	58150
Rossignol S	58150
1998	58163
Kinematic analysis of recovered locomotor movements	58169
Kinematic analysis	58169
recovered locomotor movements	58191
the hindlimbs	58224
paraplegic rats	58241
monoaminergic embryonic neurons	58275
Ann NY Acad Sci 860:521 -- 523 .	58308
Ann NY Acad Sci 860:521	58308
523	58332
Ribotta MG	58337
Provencher J	58349
Feraboli-Lohnherr D	58363
Rossignol S	58384
Privat A	58397
Orsal D -LRB- 2000 -RRB- Activation	58407
Orsal D	58407
2000	58416
Activation	58422
locomotion	58436
adult chronic spinal rats	58450
transplantation of embryonic raphe cells	58491
transplantation	58491
embryonic raphe cells	58510
a precise lumbar level	58546
J Neurosci 20:5144 -- 5152 .	58570
J Neurosci 20:5144	58570
5152	58590
Rossignol S	58596
Bouyer L	58609
Barthelemy D	58619
Langlet C	58633
Leblond H -LRB- 2002 -RRB- Recovery	58644
Leblond H -LRB- 2002 -RRB-	58644
Leblond H	58644
2002	58655
locomotion in the cat following spinal cord lesions	58673
locomotion	58673
the cat following spinal cord lesions	58687
the cat	58687
spinal cord lesions	58705
Brain Res Brain Res Rev 40:257 -- 266 .	58726
Brain Res Brain Res Rev 40:257	58726
Brain	58726
Res Brain Res Rev 40:257	58732
266	58757
Schnell L	58762
Schneider R	58773
Kolbeck R	58786
Barde YA	58797
SchwabME -LRB- 1994 -RRB- Neurotrophin-3	58807
SchwabME	58807
1994	58817
Neurotrophin-3	58823
corticospinal tract	58860
development	58887
adult spinal cord lesion	58909
Nature 367:170 -- 173 .	58935
Nature 367:170	58935
173	58950
Schwab ME	58955
Bartholdi D -LRB- 1996 -RRB- Degeneration	58966
1996	58979
regeneration of axons in the lesioned spinal cord	59002
regeneration	59002
axons in the lesioned spinal cord	59018
axons	59018
the lesioned spinal cord	59027
Physiol Rev 76:319 -- 370 .	59053
Physiol Rev 76:319	59053
370	59073
Siddall P , Xu CL , Cousins	59078
Siddall P	59078
Xu CL , Cousins	59089
Xu CL	59089
Cousins	59096
1995	59107
Allodynia following traumatic spinal cord injury in the rat	59113
Allodynia	59113
traumatic spinal cord injury in the rat	59133
traumatic spinal cord injury	59133
the rat	59165
NeuroReport 6:1241 -- 1244 .	59174
NeuroReport 6:1241	59174
1244	59193
Silver J , Miller JH -LRB- 2004 -RRB- Regeneration beyond the glial scar .	59199
Silver J	59199
Miller JH -LRB- 2004 -RRB- Regeneration beyond the glial scar	59209
Miller JH -LRB- 2004 -RRB- Regeneration	59209
Miller JH -LRB- 2004 -RRB-	59209
Miller JH	59209
2004	59220
the glial scar	59246
Nat Rev Neurosci 5:146 -- 156 .	59262
Nat Rev Neurosci	59262
5:146 -- 156	59279
Steward O	59291
Zheng B	59302
Tessier-Lavigne M -LRB- 2003 -RRB- False resurrections	59311
Tessier-Lavigne M	59311
2003	59330
False resurrections	59336
distinguishing	59357
spared axons in the injured central nervous system	59389
spared axons	59389
the injured central nervous system	59405
J Comp Neurol 459:1 -- 8 .	59441
J Comp Neurol 459:1	59441
8	59462
Takami T	59465
Oudega M	59475
Bates ML	59485
Wood PM	59495
Kleitman N	59504
Bunge MB -LRB- 2002 -RRB- Schwann cell	59516
Bunge MB -LRB- 2002 -RRB- Schwann	59516
2002	59526
cell	59540
olfactory ensheathing glia transplants	59553
hindlimb locomotor performance	59600
the moderately contused adult rat thoracic spinal cord	59634
adult rat	59658
J Neurosci 22:6670 -- 6681 .	59690
J Neurosci 22:6670	59690
6681	59709
Weidner N	59715
Blesch A	59726
Grill RJ	59736
Tuszynski MH	59746
1999	59760
Nerve growth factorhypersecreting Schwann cell grafts	59766
Nerve growth	59766
Schwann cell grafts	59800
spinal cord axonal growth and remyelinate central nervous system axons	59838
a phenotypically appropriate manner that correlates with expression of L1	59912
a phenotypically appropriate manner	59912
expression of L1	59969
expression	59969
L1	59983
J Comp Neurol 413:495 -- 506 .	59987
J Comp Neurol 413:495	59987
506	60009
West NR , Collins GH -LRB- 1989 -RRB- Cellular changes	60014
West NR , Collins GH -LRB- 1989 -RRB-	60014
West NR	60014
Collins GH -LRB- 1989 -RRB-	60023
Collins GH	60023
1989	60035
repair of a cryogenic spinal cord injury in the rat	60065
repair	60065
a cryogenic spinal cord injury in the rat	60075
a cryogenic spinal cord injury	60075
the rat	60109
an electron microscopic study	60118
an electron	60118
microscopic study	60130
J Neuropathol Exp Neurol 48:94 -- 108 .	60149
J Neuropathol Exp Neurol 48:94	60149
108	60181
Woerly S	60186
Doan VD	60196
Sosa N	60205
de Vellis J	60213
Espinosa-Jeffrey A	60226
2004	60246
Prevention of gliotic scar formation by NeuroGel	60252
Prevention	60252
gliotic scar formation by NeuroGel	60266
gliotic scar formation	60266
NeuroGel	60292
partial endogenous repair of transected cat spinal cord	60308
partial endogenous repair	60308
transected cat spinal cord	60337
J Neurosci Res 75:262 -- 272 .	60365
J Neurosci Res 75:262	60365
272	60387
Xu XM	60392
Guenard V	60399
Kleitman N	60410
Aebischer P	60422
Bunge MB	60435
1995a	60445
A combination of BDNF and NT-3	60452
A combination	60452
BDNF and NT-3	60469
supraspinal axonal regeneration	60492
Schwann cell grafts in adult rat thoracic spinal cord	60529
Schwann cell grafts	60529
adult rat thoracic spinal cord	60552
adult rat	60552
thoracic spinal cord	60562
Exp Neurol 134:261 -- 272 .	60584
Exp Neurol 134:261	60584
272	60603
Xu XM	60608
Guenard V	60615
Kleitman N	60626
Bunge MB	60638
1995b	60648
Axonal regeneration into Schwann cell-seeded guidance channels	60655
Axonal regeneration	60655
Schwann cell-seeded guidance channels	60680
transected adult rat spinal cord	60731
J Comp Neurol 351:145 -- 160 .	60765
J Comp Neurol 351:145	60765
160	60787
Xu XM	60792
Chen A	60799
Guenard V	60807
Kleitman N	60818
Bunge MB -LRB- 1997 -RRB-	60830
Bunge MB	60830
1997	60840
Schwann cell transplants	60855
axonal regeneration	60888
both the rostral and caudal stumps	60913
the rostral	60918
caudal stumps	60934
transected adult rat spinal cord	60951
J Neurocytol 26:1 -- 16 .	60985
J Neurocytol 26:1	60985
16	61003
Ye JH	61007
Ye	61007
JH	61010
Houle JD -LRB- 1997 -RRB- Treatment	61014
Houle JD -LRB- 1997 -RRB-	61014
Houle JD	61014
1997	61024
the chronically injured spinal cord with neurotrophic factors	61043
the chronically injured spinal cord	61043
neurotrophic factors	61084
axonal regeneration	61117
supraspinal neurons	61142
Exp Neurol 143:70 -- 81 .	61163
Exp Neurol 143:70	61163
81	61181
Yick LW	61185
Cheung PT	61194
So KF , WuW -LRB- 2003 -RRB-	61205
So KF	61205
WuW -LRB- 2003 -RRB-	61212
WuW	61212
2003	61217
Axonal regeneration	61223
Clarke 's neurons	61246
Clarke 's	61246
the spinal cord injury scar after treatment with chondroitinase ABC	61270
the spinal cord injury scar	61270
treatment with chondroitinase ABC	61304
treatment	61304
chondroitinase ABC	61319
Exp Neurol 182:160 -- 168 .	61339
Exp Neurol	61339
182:160 -- 168	61350
